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Introduction
At  present,  hearing  impairment  is  the  most  common  perception  disorder.1,2
Causes of hearing impairment are wide-ranging and include genetic aberrations,
perinatal infection, noise, ototoxic drugs and cochlear trauma. Hearing loss can
arise before speech development (prelingual) or afterwards (postlingual). The
frequency of early childhood sensorineural hearing impairment is estimated to be
1 in 650 newborns.3-5 More than half of the prelingual cases are genetically
determined and about 75% of those are accounted for by non-syndromic forms3,4,6.
Far more people are affected by postlingual hearing impairment than by
prelingual hearing impairment. Environmental factors and aging play important
roles. Several monogenic forms also exist and they mostly follow an autosomal
dominant pattern of inheritance. Non-syndromic hearing impairment can be
further categorized into types of inheritance: approximately 77% of the cases are
autosomal recessive, 22% are autosomal dominant, 1% are X-linked and < 1% are
mitochondrial.4 Autosomal dominant loci have been designated with the prefix
”DFNA”,  recessive  loci  with  “DFNB”,  X-linked  loci  with  “DFN”  and  modifying
loci with “DFNM”. Y-linked inheritance has been proposed in one Chinese family,
which has been designated DFNY1.7
Since the first successful attempts to detect hearing impairment loci and genes in
1992, rapid progress has been made. By now, 54 loci and 21 genes have been
identified in non-syndromic autosomal dominant types of hearing impairment.
An overview of the human hearing impairment loci and genes can be found on
the Hereditary Hearing Loss Homepage (Van Camp G, Smith RJH. Hereditary
Hearing Loss Homepage. URL: http:// webhost.ua.ac.be/hhh/).
The complexity of hereditary hearing impairment is demonstrated by the
involvement of various genes in the dominant and recessive non-syndromic forms
and also in the non-syndromic and syndromic forms. For example, mutations in
the myosin VIIa gene (MYO7A) can cause DFNA11,8,9 DFNB2,10,11 Usher Type 1B12
and atypical Usher syndrome.13,14
Historical overview
Systematic clinical research into hereditary hearing impairment started in the mid
19th century15,16. Two patterns of inheritance were identified: direct (later called
autosomal dominant) and indirect (or autosomal recessive).15, 17,18  Mendel’s laws19
were rediscovered early in the 20th century, but for many years it had been
understood that there was a relationship between autosomal recessive inherited
diseases and the degree of consanguinity. As the latter was fairly high in the 19th
century (about 30% in some areas), the genetic disadvantages of consanguineous
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marriages became well documented.16,17 The earliest reports on the most
frequently occurring hereditary hearing impairment syndromes appeared at the
turn of the century. In 1922, Albrecht was the first to write about autosomal
dominant hearing impairment without any associated abnormalities.20
In the nineteen sixties and the seventies, encyclopaedic books were launched on
hereditary hearing impairment syndromes.21-26 About ten years later, gene linkage
studies were initiated to trace the loci for the genes involved in syndromic hearing
impairment.27 Shortly  afterwards,  the  non-syndromic  forms were  addressed and
the first successful linkage was accomplished in Nijmegen for the X-linked
progressive mixed deafness syndrome with perilymphatic gusher during stapes
surgery.28,29 The associated features in this disease were mostly subclinical, which
led to it being categorized as non-syndromic DFN3. Clearly, the X-linked pattern
of inheritance facilitated this locus identification.28
In the past ten years, there has been an enormous increase in the identification of
loci and genes owing to progress in the Human Genome Project and the
availability of cochlear-specific cDNA libraries and mouse models for hearing
impairment. These developments in human genetics encouraged the Nijmegen
ORL department to extend its genetic research towards non-syndromic autosomal
dominant hearing impairment, initially in collaboration with the Department of
Medical Genetics of the University of Antwerp and, since 2000, principally with
the Otogenetic Department of the Radboud University Nijmegen Medical Centre.
Many contributions have been made to describe the phenotypes and genotypes of
a series of autosomal dominant forms of hearing impairment, especially DFNA2,
DFNA4, DFNA5, DFNA6/14, DFNA8/12, DFNA9, DFNA10, DFNA11, DFNA13,
DFNA20/26, DFNA21 and DFNA31. This thesis was part of the ongoing Nijmegen
otogenetic research projects and focused on the clinical and genetic headway
regarding DFNA5, DFNA9 and DFNA11.
Clinical Classification
Only a few clinical criteria were available to differentiate between types of
hereditary hearing impairment until the relevant loci and genes were identified.
Hearing impairment was classified not only on the basis of features of conductive
or  mixed  hearing  loss,  but  also  on  age  of  onset,  severity  and  progression  of
hearing impairment, unilaterality or bilaterality of hearing impairment,
configuration  of  the  audiograms  and  the  presence  or  absence  of  vertigo.  The
shape of the audiogram was a very important characteristic, because it could
distinguish hearing impairment into low, mid, high and all frequency deficits.
Consequently, 16 types have been described in “Genetic and Metabolic Deafness”
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by Konigsmark and Gorlin24.  In  the  years  that  followed,  so  many  new  types  of
hereditary hearing impairment were identified that the existing nomenclature had
to  be  further  categorized  into  DFNA,  DFNB,  DFN  and  DFNM,  as  mentioned
above.
Table  1  presents  the  genotype  of  the  different  DFNA  types.  As  so  many  of  the
numerous  autosomal  dominant  types  are  fairly  rare,  it  is  of  value  to  use  the
clinical criteria to predict which type might be involved in a given trait, in order to
perform  linkage  to  a  specific  locus  or  mutation  analysis  on  a  specific  gene.  To
facilitate this, the method of Age Related Typical Audiograms (ARTA) was
introduced.30 This tool can be used to make phenotype “fingerprints”, so that it
becomes  possible  to  test  whether  the  phenotype  of  a  new  family  is  significantly
different from a known DFNA type.30 Huygen et al.31 used a phenotypic
classification with five categories, similar to the one described by Mazzoli et al.: 32
high-frequency, mid-frequency, and low-frequency hearing impairment, hearing
impairment at all frequencies and residual hearing. In non-syndromic autosomal
dominant types of hearing impairment, high-frequency hearing impairment
(downsloping audiogram) is present in DFNA2, DFNA3, DFNA5, DFNA7,
DFNA8/12, DFNA9, DFNA15, DFNA16, DFNA17, DFNA20/26, DFNA23,
DFNA24, DFNA30, DFNA36, DFNA42, DFNA47 and DFNA48. Mid-frequency
hearing impairment phenotypes (U-shaped audiogram) are present in DFNA8/12,
DFNA13, DFNA44 and DFNA49. Low-frequency hearing impairment is present
in DFNA1, DFNA6/14/38 and DFNA54, while hearing impairment at all
frequencies (flat audiogram) is present in DFNA4, (DFNA8/12), DFNA10,
DFNA11, DFNA18, DFNA21, DFNA25, DFNA28, DFNA31, DFNA41, DFNA43
and DFNA50. Residual hearing is only seen in DFNA22.31
Other clinical characteristics are also useful, such as age of onset, progression and
severity of the hearing loss, intra-familial variability, speech recognition scores,
presence  or  absence  of  vestibular  dysfunction  and  tinnitus  and  radiographically
detectable cochleovestibular anomalies. Therefore, the search for the locus can be
guided by these clinical data and can be limited to some well-known DFNA types
before employing the more costly approach of a total genome scan to identify the
genetic defect.
An  overview  is  given  of  DFNA5,  DFNA9  and  DFNA11  in  the  following  part  of
this introduction, because these three DFNA types formed the focus of this thesis.
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Table 1. Description of phenotype, gene linkage and gene identification
Locus Relevant Clinical
Description
Number of
Families*
Site of Mutation or
Amino Acid Change
Gene Localization
DFNA1 León 1981, CR33?
Lalwani 199834
1 Costa Rican35 c.IVS17+1 G>T35 DIAPH135 5q3136
DFNA2 Marres 1997, NL37?
Kunst 199838
Ensink 200039
Akita 200140
De Leenheer 200241,42
Stern 200343
Topsakal 200544
15
1 Belgian45
1 Japanese46
1 Dutch47
5 Dutch,
Japanese40,44,45,48
1 USA49
1 French50
2 USA, French45
1 Dutch45
c.211_223del45
c.211delC46
p.Leu274His47
p.Trp276Ser40,44,45,48
p.Leu281Ser49
p.Gly285Ser50
p.Gly285Cys45
p.Gly321Ser45
KCNQ450 1p3448, 51
Lacking clinical data 1 Chinese52
1 Chinese52
p.Glu183Lys52
p.Arg180TER52
GJB352 1p35.151,52
DFNA3 Tekin 2001, USA53?
Denoyelle 200254
Primignani 200355
14
1 UK56
3 French/USA53, 57
1 Italian58
1 Egyptian59
2 French/Italian 60,61
1 Austria/Czech62
1 Chinese63
1 Italian55
1 French64
1 Chinese63
p.Met34Thr56 ^
p.Trp44Cys53, 57
p.Thr55Asn58
p.Arg75Trp59
p.Arg75Gln60,61
p.Arg143Gln62
p.Ala171Thr63
p.Asp179Asn55
p.Cys202Phe64
c.299_300delAT63
GJB256 13q11-1265
Lacking clinical data 1 Italian66 p.Thr5Met66 GJB666 13q1267
DFNA4 Pusch 2004, DE68?
Yang 200569
9
1 German70
1 German69
sporadic case70
1 Belgian70
1 Italian70
p.Ser7X70
p.Ser120Leu69
p.Gly376Cys70
p.Arg726Ser70
p.Leu976Phe70
MYH1470 19q13.3368,71
DFNA5 Huizing 1966, NL72?
Huizing 198373
De Leenheer 200274
Bischoff 200575
3
1 Dutch76
1 Dutch75
1 Chinese77
c.IVS7 1189del/127ins76
c.IVS7-6C>G75
c.IVS7-22_-20delCTT77
DFNA576 7p1578
DFNA6/14/
DFNA38
Vanderbilt gr. ‘68, USA79?
Kunst 199980
Bom 200281
Lesperance 200382
Pennings 200383
23-26
1 isolated person84
1 Japanese85
1 Dutch84
1 Dutch84
2 German/Dutch84, 86
1 German87
3 Canadian/
Dutch/USA83, 86
1 Dutch84
1 Swiss89
1 USA86
1 UK84
1 USA86
2 USA84, 86
p.Lys193Gln84
p.Lys634Thr85
p.Gly674Glu84
p.Gly674Val84
p.Thr699Met84, 86
p.Lys705Asn87
p.Ala716Thr83, 86
p.Ile767del84
p.Asp771His89
p.Val779Met86
p.Ser807Arg84
p.Leu829Pro86
p.Gly831Asp84, 86
WFS186 4p16.386,91,92
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1 Japanese90
1 USA89
p.Ala844Thr90
p.Arg859Pro89
DFNA7 Lacking clinical data 1 Norwegian93 - - 1q21-2393
DFNA8/12 Govaerts 1998, BE94?
Iwasaki 200295
Plantinga 200696
9
1 Swedish97
1 Turkish98
1 French99
1 Belgian100
1 Belgian100
1 Spanish101
1 Austrian100
1 Dutch96
1 Japanese95
p.Cys1057Ser97
p.Cys1509Gly98
p.Cys1619Ser99
p.Leu1820Phe100
p.Gly1824Asp100
p.Cys1837Gly101
p.Tyr1870Cys100
p.Arg1890Cys96
p.Arg2021His95
TECTA101 11q22-24
102,103
DFNA9 Verhagen 1988, NL?104
Verhagen 1989, 2001105-106
Bom 1999, 2003107, 108
Verstreken 2001109
Kemperman 2002,
2005110,111
Lemaire 2003112
Bischoff 2005, 2006113,114
Street 2005115
Pauw 2006116
many
1 USA119
1 Dutch120
2 Dutch/USA119
1 Hungarian121
1 Dutch122
1 Australian123
1 USA119
1 Japanese124
1 USA115
p.Pro51Ser117,118
p.Val66Gly119
p.Gly87Trp120
p.Gly88Glu119
p.Val104del121
p.Ile109Thr122
p.Ile109Asn123
p.Trp117Arg119
p.Ala119Thr124
p.Cys542Phe115
COCH119 14q12-13125
DFNA10 Verstreken 2000, BE126?
De Leenheer 2001,
2002127,128
4
1 USA129
1Belgian129
1 Hungarian130
c.1468_1469insAA129
p.Arg587X129
c.1558_1559insTTTG130
EYA4129 6q22-23131
DFNA11 Tamagawa 1996, JP8?
Tamagawa 2002132
Street 2004133
Bischoff 2006134
5
1 Italian135
1 Dutch136
1 USA133
1 German137
1 Japanese9
p.Ala230Val135
p.Asn458Ile136
p.Gly722Arg133
p.Arg853Cys137
p.Ala886_Lys888del9
MYO7A9 11q12.3-218
DFNA13 Kunst 2000, NL138?
De Leenheer 2001 2002,
2004139-141
2
1 Dutch142
1 USA142
p.Gly323Glu142
p.Arg549Cys142
COL11A2
142
6p21.3143
DFNA15 Frydman 2000, IL144?
Gottfried 2002145
1 Israelian146 c.880_887del 146 POU4F3146 5q31-33146
DFNA16 Lacking clinical data 1 Japanese147 - - 2q23-24.3147
DFNA17 Lalwani 2002, USA148? 1 USA149 p.Arg705His149 MYH9149 22q12-13150
DFNA18 Lacking clinical data 1 German151 - 3q22151
DFNA19 - - - - 10 pcent152
DFNA20/26 Teig 1968, NO153?
Elfenbein 2001154
DeWan155
Kemperman 2004 156
6
1 USA157
1 USA157
1 USA157
1 USA157
1 Dutch158
1 Norwegian159
p.Thr89Ile157
p.Lys118Met157
p.Pro332Ala157
p.Pro264Leu157
p.Thr278Ile158
p.Val370Ala159
ACTG1157 17q25160
DFNA21 Kunst 2000, NL161? 1 Dutch161 - - 6p22-24 161,162
DFNA22 Topsakal 2006, BE163? 2
1 Italian163 p.Cys442Tyr163
MYO6164 6q13164
DFNA23º Lacking clinical data 1 Swiss/German165 - SIX1166 14q21-22165
DFNA24 Santos 2006, CH167? 1 Swiss/German168 - - 4q35ter168
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DFNA25 Lacking clinical data 1 USA169 - - 12q22-24169
DFNA27 - - - - 4q12170
DFNA28 Lacking clinical data  1 USA171 c.1609_1610insC171 TFCP2L3171 8q22171
DFNA29 - - - reserved -
DFNA30? Lacking clinical data 1 Italian172 - - 15q25-26172
DFNA31? Ensink 2001, NL173? 1 Dutch174 - - 6p21.3174
DFNA32 - - - - 11p15175
DFNA33 - - - reserved -
DFNA34 Lacking clinical data - -  - 1q44176
DFNA35 - - - reserved -
DFNA36 Makishima 2004, USA177? 1 USA178 p.Asp572Asn178 TMC1178 9q13-21178
DFNA37 Lacking clinical data 1 USA179 - - 1p21179
DFNA39† Lacking clinical data 2 Chinese180 DSPP180 4q21.3180
DFNA40 - - - reserved 16p12
DFNA41 Lacking clinical data 1 Chinese181 - - 12q24-qter181
DFNA42 Lacking clinical data 1 Chinese182 - - 4q28182
DFNA43 Lacking clinical data 1 Italian183 - - 2p12183
DFNA44 Lacking clinical data 1 Spanish184 - - 3q28-29184
DFNA45 - - - reserved -
DFNA46 - - - reserved -
DFNA47 Lacking clinical data 1 Italian185 - - 9p21-22185
DFNA48 Lacking clinical data 1 Italian
8 isolated persons:
186
p.Arg93X186
p.Ser116_Tyr117insSer186
p.Val306Met186?
p.Glu385Asp186
p.Gly662Glu186?
p.Gly674Asp186?
p.Ser797Phe186
p.Ser910Pro186?
MYO1A186 12q13-14187
DFNA49 Lacking clinical data 1 Spanish188 - - 1q21-23188
DFNA50 Lacking clinical data 1 Spanish189 - - 7q32189
DFNA51 - - - reserved 9q21
DFNA52 - - - reserved 4q28
DFNA53 Lacking clinical data 1 Chinese190 - - 14q11-12190
DFNA54? Lacking clinical data 1 Swiss191 - - 5q31191
X: stopcodon, del; deletion, ins; insertion; pcent; pericentral, c.; changes at the coding DNA level, p.; changes
at  the  protein  level;  gr.;  group.*At  first  the  number  of  all  families  is  reported,  below this,  the  number  and
origin of the families with a known mutation are reported; ? Indicates first clinical description together with
the  country  abbreviation;  ^  This  mutation  is  believed  not  to  be  a  disease  causing  mutation,  but  a
polymorphism; º One patient with solitary left hypoplastic kidney with vesicoureteral reflux and progressive
renal failure, suggesting BOR syndrome166; ?DFNA30 shows overlap with OTSC1, a locus for otosclerosis, but
patients do not have signs of otosclerosis171; ? This family was first linked to DFNA13; † Not a non-syndromic
form  of  hearing  impairment,  but  dentinogenesis  imperfecta,  associated  with  hearing  impairment  in  some
families; ? No family records available, no certainty of autosomal dominant inheritance; ? Shows overlap
with DFNA15 but with different phenotype.
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DFNA5
Clinical characteristics
At present, three different DFNA5 families have been described. The first family
in  which  the  locus  was  identified  was  of  Dutch  origin  and  showed  progressive
symmetrical hearing loss that started at the high frequencies.72,73,192-195 Later,
another Dutch family and a Chinese family were encountered.75,77 The audiograms
had so-called Z-shaped profiles.74,75 Clinical  data  on  the  two  Dutch  families
demonstrated similar pure-tone hearing thresholds with more favourable speech
recognition in the second family, owing to better speech frequency thresholds in
the first four decades (annual threshold deterioration (ATD) of 1 to 4 versus 1.2 to
1.4 dB per year at 2 to 8 kHz). Vestibular function was normal in the two Dutch
families. Unfortunately, it was not possible to make comparisons with the pheno-
type of the Chinese family because of the lack of clinical data in the Chinese
report. Table 2 lists the clinical and genetic data of the three DFNA5 families.
Table 2. Phenotype and genotype of DFNA5
Origin Site of Mutation Effect of
Mutation
Hearing
Onset
Hearing
Impairment
Vestibular Dysfunction
Subjective    Objective
Netherlands IVS7,
1189bp del/127bp ins
Exon 8 del 5-15 y high frequency absent absent
Netherlands IVS7-6 C>G Partially
Exon 8 del
0-40 y high frequency absent 1 hyperreflexia
China IVS7-20-22del CTT Exon 8 del 7-30 y high frequency not
available
not available
IVS, intervening sequence (intron); bp, base pair; del, deletion, ins, insertion, y, years.
Genetic aspects
DFNA5 was mapped to chromosome 7p15 in 1995.78 By positional cloning, a
complex insertion/deletion mutation was found in intron 7 that caused skipping
of exon 8 in the messenger RNA (mRNA). This leads to premature termination of
the encoded protein.76 In  the  second  Dutch  DFNA5  family,  a  mutation  was
present in the splice acceptor site of intron 7 that caused skipping of exon 8 in part
of the mRNA.75 Furthermore, another mutation in the Chinese DFNA5 family
with  deletion  in  intron  7  also  caused  skipping  of  exon  8  in  the  mRNA.77 All
mutations  have the  same effect  on the  mRNA and the  protein.  Therefore,  it  was
hypothesized that the effect of skipping of exon 8 is crucial in the development of
hearing impairment in DFNA5.
At  present,  little  is  known  about  the  function  of  the  DFNA5  protein.  It  is
expressed in the cochlea and placenta and at low levels in the heart, brain, kidney,
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lung, liver, pancreas and skeletal muscle.76,196 In the mouse, Dfna5 expression is
present in the developing and mature cochlea.197
Van Laer et al. generated Dfna5 knockout mice that did not show cochleo-
vestibular impairment.1 Detailed analysis of the cochlea revealed that even at
birth, there were significant differences in the number of fourth row outer hair
cells between the knockout mice and the wild-type mice. In view of the absence of
hearing loss in the knockout mice, it was hypothesized that DFNA5-related
hearing  impairment  in  humans  is  caused  by  a  gain  of  function.  This  was
supported by the toxic effect of mutant DFNA5 on yeast cells and mammalian
cells and their loss of viability.1,2,198
Dunø et al. also suggested that DFNA5 mutations  caused  a  gain  of  function,
because two cases with deletion in the 7p14-p15 locus that included DFNA5 had
normal hearing.199
Examination of Dfna5 knockdown zebrafish revealed malformation of the semi-
circular canals and pharyngeal cartilage. The Dfna5 knockdown phenotype
resembled that of the Jekyll mutant, with a mutated ugdh gene. It also showed loss
of  ugdh  expression  and  low  hyaluronic  acid  levels.200 Hyaluronic acid was
considered to be important in the differentiation of cartilage and the projection
outgrowth of the protrusions of the semicircular canals in the embryonic ear.201
Reductions in hyaluronic acid may lead to uncoordinated growth and collapse of
the protrusions, with destruction of the semicircular canals. The DFNA5 mutation
is not a null mutation. Therefore, it is difficult to suggest a correlation between the
zebrafish phenotype and DFNA5.
Pejvakin,  a  protein  encoded  by DFNB59,  is  a  member  of  the  DFNA5DC  protein
family that also includes DFNA5.202,203 DFNB59 causes non-syndromic, prelingual,
severe to profound hearing impairment with auditory neuropathy and normal
cochlear hair cell function. As DFNA5 and pejvakin occupy homologous regions it
has been suggested that they are paralogs. 203 The function of pejvakin is
unknown,  so  the  homology  between  the  proteins  does  not  provide  any  clues
about DFNA5 function.
It has been hypothesized that DFNA5 is involved in different forms of cell death,
apoptosis and necrosis during the development of the ear, or later in life. 1,198
DFNA5 is also believed to play a role in tumour biology.204,205
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DFNA9
Clinical characteristics
Audiometry
DFNA9 causes autosomal dominant progressive sensorineural hearing
impairment, predominantly at the high frequencies, with progressive vestibular
dysfunction.104-113,116,119,122,123,206-210 The first clinical description comprised a Dutch
DFNA9 family, before gene linkage studies had been performed for non-
syndromic autosomal dominant types of hearing loss.104 Ten different mutations
have been identified in DFNA9 in the COCH (coagulation factor C homology)
gene: Val66Gly, Gly88Glu, Trp117Arg,119 Pro51Ser,117,118 Ile109Asn,123 Ala119Thr,124
Val104del,121 Cys542Phe,115 Gly87Trp120 and Ile109Thr122 (Table 3). Many families in
the Netherlands and Belgium are known to have the Pro51Ser founder mutation211
and two families are known to have the Gly88Glu mutation.111,119 All the other
DFNA9 mutations have been identified in just one family. Hearing impairment
started in the second to third decades in the American families with the Val66Gly
and Trp117Arg mutations.119,209 In  contrast,  it  developed  from  the  fourth  to  fifth
decade onwards in all the other DFNA9 families.111,116-119,121-124 The age of onset in
the family with the Cys542Phe mutation has not yet been determined.115 ATD
values  were  around  2  to  7  dB,  which  eventually  led  to  (sub)residual  hearing
threshold levels.107,110,111,113,117 Speech recognition was fairly poor, deteriorated
rapidly and resembled presbyacusis, but at a younger age.116
A  high  prevalence  of  vascular  disease  was  found  in  two  families  with  the
Pro51Ser mutation.105,107 Although it has been suggested that DFNA9 causes
strangulation of cochlear nerves and degeneration of hair cells, cochlear
implantation appeared to be successful in DFNA9 patients with severe to
profound hearing loss.212-214
Vestibular function
The vestibular  dysfunction that  is  associated with DFNA9 is  progressive  and its
expression varies between families with different mutations. In the families with
the Pro51Ser and Ile109Asn mutations, the vestibular phenotype was fully
penetrant.113,123 In the family harbouring the Gly87Trp substitution and the two
families with the Gly88Glu mutation, expression was 89(%) and 40-50(%),
respectively.111,116,119 Expression was also incomplete in the families harbouring the
Val66Gly, Trp117Arg and Ile109Thr mutations, but it was not clear in the family
with the Ala119Thr mutation.122,124,209,215 In the family with the Val104del mutation,
vestibular symptoms were only reported in the proband, who had vestibular
areflexia.121 No  subjective  vestibular  dysfunction  was  described  in  the  first  four
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decades of life in the family that carried the Cys542Phe substitution.115 Vestibular
tests showed dysfunction of the horizontal semicircular canal and probably the
saccular otolith in two of three persons. 115
In families with the Pro51Ser mutation vestibular impairment started at an earlier
age  and  showed  more  rapid  progression.  Ultimately,  loss  of  function  was  more
complete than the hearing impairment.113 In the Dutch families that carry the
Gly88Glu and Gly87Trp mutations, the frequency of vestibular areflexia was
significantly lower and the age of onset of vestibular impairment seemed to be
higher than in the families with the Pro51Ser substitution. Age of onset of hearing
impairment was similar in all families harbouring the three mutations.111,116 The
age of onset of vestibular impairment in the family with the Val66Gly mutation
was extremely variable and the symptoms started a few years later than the
hearing impairment.215
Ménière-like vertiginous attacks have been reported in families that carry the
Pro51Ser founder mutation and also in other DFNA9 families.106,109,112,118,123,124,208
However, unlike Ménière’s disease, DFNA9 causes non-fluctuating high-
frequency hearing loss, without any signs of endolymphatic hydrops. In addition,
COCH mutations were not found in patients with Ménière’s disease.124,216
Consequently, the association appears to be epiphenomenal.215
Vertical corneal striae
Recently, subclinical vertical corneal striae have been found in three DFNA9
families, two of whom were carrying the Pro51Ser mutation and one the Gly88Glu
mutation.114 No  vertical  corneal  striae  were  present  in  the  general  Dutch
ophthalmologic population or in a fourth family with the Gly87Trp mutation,
except in one family member who had keratoconus. The striae were observed
from the age of 47 years onwards in 32 individuals, of whom 27 individuals had a
COCH mutation.  Most  frequent  symptoms  were  dry  and  injected  eyes  and
instability of refraction and vision. We found a significant association between the
corneal striae and the midlife-onset cochleovestibular dysfunction in the three
DFNA9 families, which suggests that these two features are caused by Pro51Ser
and Gly88Glu COCH mutations.114 A sequence variant in a neighbouring gene
might also cause the cosegregation of the corneal phenotype with the DFNA9
mutations. However, it is unlikely because the striae were present in three DFNA9
families with two different COCH mutations and this phenomenon has not been
described previously. The suggestion that COCH gene  mutations  caused  the
vertical corneal striae was supported by the identification of co-deposits of cochlin
and acidophilic mucopolysaccharide in the trabecular meshwork of patients with
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primary open angle glaucoma and in glaucomatous DBA/2J mice with
progressive hearing loss, which were absent in age-matched control donor
eyes.217,218 This theory was also sustained by the detection of COCH gene
transcripts in the human cornea using RT-PCR114 and in a cDNA library
constructed using RNA from the anterior segment of the zebrafish eye.219
Table 3. Phenotype and genotype of DFNA9
Origin Exon Amino
Acid
Change
Affected
Domain
Hearing
Onset
Hearing
Impairment
Vestibular Dysfunction
Subjective   Objective
Corneal
Involvement
Netherlands 4 Pro51Ser LCCL 40 y high
frequency
100% 100% 2 families
USA 4 Val66Gly LCCL 2nd-3rd
decade
high
 frequency
1 out of 3 3 out of 3 not available
Netherlands 5 Gly87Trp LCCL 43 y high
frequency
15 out of
28
10 out of 12 absent
USA/
Netherlands
5 Gly88Glu LCCL 46-49 y high
frequency
40 (%)** 40%** 1 family
Hungary 5 Val104del LCCL 32 y* high
frequency
1 out of 1 areflexia* not available
Netherlands 5 Ile109Thr LCCL 43 y high
frequency
5 out of 11 4 out of 7 absent
Australia 5 Ile109Asn LCCL 4th –5th
decade°
high
frequency
100 % 100 % not available
USA 5 Trp117Arg LCCL early 3rd
decade
high
frequency
some ? not available
Japan 5 Ala119Thr LCCL 30-35 y high
frequency
not
available
not
available
not available
USA 12 Cys542Phe vWFA 2 not
available
high
frequency
absent 2 out of 3,
no areflexia
not available
y, years;  * 1 patient available; ** Data derived from the Dutch Gly88Glu family, ° in erratum corrected123
Genetic aspects
In 1996, DFNA9 was found to be linked to chromosome 14q12-13.125 The COCH
gene  was  isolated  by  using  a  human  foetal  cochlear  cDNA  library  with  high
expression in the cochlear and vestibular labyrinth.220,221 COCH has 12 exons that
encode  an  extracellular  matrix  protein,  called  cochlin.222 Cochlin is a stable
component of the inner ear and is highly conserved between species.220,221 This
protein contains a signal peptide, an LCCL domain and two von Willebrand
factor A-like domains (vWFA1 and vWFA2). The two domains are involved in
haemostasis, the complement and immune system, and the extracellular matrix
assembly.223 The LCCL domain refers to the three proteins that contain the module
Limulus factor C clotting protein, cochlin and late gestation lung protein Lgl1. Its
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module is an autonomous folding domain, present in various extracellular
modular proteins.224 As  Factor  C  is  an  endotoxin-sensitive  serine  protease  that
operates in the Limulus defence system, the LCCL domain plays an important role
in antibody-independent host defence.225 The expression of Lgl1 in foetal lungs
coincides  with  the  production  of  pulmonary  surfactant  and  might  assist  in  its
antimicrobial activity.224, 226
Liepinsh et al. demonstrated that all the then known mutations (Pro51Ser,
Val66Gly, Gly88Glu, Ile109Asn, Trp117Arg) occur in the LCCL domain. With the
exception  of  Trp117Arg,  all  mutations  in  the  LCCL  domain  tested  disrupt  its
normal structure and lead to protein misfolding of this domain.226 The mutation
that causes the Cys542Phe substitution however, is located in the vWFA2
domain.115 Cochlin  is  expressed  in  the  cochlear  fibrocytes  of  the  spiral  ligament,
spiral  limbus  and  osseous  spiral  lamina  and  in  the  fibrocytes  of  the  stroma  that
underlie  the  sensory  epithelium  of  the  crista  ampullaris  of  the  semicircular
canals.222,227 Cochlin is secreted via the endoplasmatic reticulum and golgi
apparatus. It is then cleaved and glycosylated.228 Cochlin expression is exclusive to
the mesodermal tissues and it is the most abundant protein in the bovine, mouse
and human cochlea. 227,229
Results of reverse transcriptase polymerase chain reaction (RT-PCR) on RNA from
EBV-transformed cell lines imply that the expression of mutant COCH transcripts
is stable, without degradation in patients with the Pro51Ser mutation.227 As  no
premature termination or truncation is caused by the known COCH mutations,
these findings support the hypothesis of a dominant negative effect in DFNA9,
rather than haploinsufficiency.227 The presence of cochlin-containing deposits in
the inner ear of DFNA9 patients (see next paragraph) and the absence of any
obvious pathology in Coch (-/-) mice at five months of age further disputes the
concept of haploinsufficiency and confirms that the cochleovestibular dysfunction
in DFNA9 is the result of toxic effects by a gain of function mechanism.227,230
Histopathology of the inner ear
The first temporal bone studies of two American DFNA9 families were reported
in 1991.209 Cellular degeneration of fibrocytes and replacement by homogeneous
glycosaminoglycan deposits  was  found predominantly  in  the  more medial  parts
of the spiral ligament, the region of the insertion of the spiral limbus into the
basilar membrane and in the stroma of the macula and crista in the vestibular
labyrinth. Families with Val66Gly, Gly88Glu, Trp117Arg and Pro51Ser mutations
showed these anomalies in the temporal bones, which suggests that all the
mutations cause the same destruction due to similar pathologic
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processes.209,212,227,231 In the labyrinth, the ampullary stroma and wall showed
distortion, collapse and thickening.227 These inner ear findings are exclusive for
DFNA9. Electron microscopic studies revealed that these acidophilic deposits
consist  of  highly  branched,  non-banded microfibrils,  that  are  believed to  lead to
disruption of the extracellular matrix assembly. Khetarpal suggested that
pathology was secondary to altered interactions between the type A von
Willebrand factor domain of cochlin and the surrounding collagens.215 Recently it
has been found that these deposits do indeed contain cochlin.227
Immunohistochemistry on post-mortem tissue from DFNA9 patients with anti-
cochlin antibodies demonstrated staining principally in the areas of the atrophied
fibrocytes of the spiral ligament, spiral limbus, spiral lamina, stroma of the crista
ampullaris and the ampullary wall. The perivascular areas in the modiolus were
also immunopositive for cochlin. Other observations were neuroepithelial and
neuronal degeneration in the inner ear. These secondary changes are caused by
degradation of the extracellular matrix, or strangulation, or interruption of the
blood supply by the accumulation of the mutant cochlin aggregates.215,227 Cochlin
deposits may aggregate in time and result in late onset progressive cochleo-
vestibular dysfunction.228
The function of Cochlin
Cochlin is believed to have a structural function in the extracellular matrix
assembly. Its von Willebrand type A domains may interact with other
components of the extracellular matrix assembly, which is crucial to the highly
structured architecture.119,221
In  autoimmune sensorineural  hearing loss,  cochlin  was found to  be  a  key target
antigen  in  immunoglobulin  and  T-cell  mediated  mechanisms.  Elevated  serum
levels of anti-cochlin antibodies have been detected in patients with autoimmune
sensorineural hearing loss.227,232 In the autoimmune-prone SWXJ mice,
experimentally induced CD4+ T-cell mediated response to cochlin as a target
antigen was reported. The mice became hearing impaired five weeks after
immunisation.233,234 Inner ear inflammation occurred at the sites with high cochlin
expression and the histopathological features in DFNA9.234 Furthermore, patients
with autoimmune sensorineural hearing loss had significantly higher numbers of
circulating T cells and higher serum cochlin-specific antibody titers than
unaffected age-matched controls.235
Cochlin may have a role in ion homeostasis. The spiral ligament, spiral lamina
and limbus are associated with K+ recycling from the hair cells to the endolymph,
through a network of gap-junctions. The cochlin deposits present at these sites in
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DFNA9 may cause obstruction of the K+ pathways that  results  in  disturbance of
ion homeostasis in the inner ear. This condition may be responsible for the
cochleovestibular phenotype.118
Identification of cochlin in the perivascular areas in the modiolus and the cochlear
duct in combination with the high prevalence of cardiovascular disease in families
with the Pro51Ser mutation,105,107 indicates  a  possible  role  of  cochlin  in  blood
vessels. This hypothesis was corroborated by the presence of von Willebrand type
A domains in cochlin, which are important in haemostasis.224
More studies are needed to provide supporting evidence of the different functions
of cochlin. In the future, a DFNA9 mouse model will further clarify the long-term
changes  in  the  inner  ear  and  eye.  This  model  is  currently  being  evaluated  by
Robertson et al.227
DFNA11
Clinical characteristics
DFNA11 causes symmetrical progressive sensorineural hearing impairment at all
frequencies and vestibular dysfunction. Five DFNA11 mutations have been
described (Table 5): Ala886_Lys888del,9 Asn458Ile,136 Gly722Arg,133 Arg853Cys137
and Ala230Val.135 The age of onset of DFNA11 varies from early childhood
(mostly) to the third decade. Audiograms can have a flat or gently downsloping
or sometimes even an ascending shape. The mean ATD is 0.56 dB per year132 or
varies between 0.3 and 0.9 dB per year, depending on the frequency134 and hearing
impairment becomes moderate to severe. Speech recognition is well preserved in
the families with the Asn458Ile and Ala886_Lys888del mutations, but it has not
been evaluated in the other families. In contrast with the recessive phenotype
DFNB2  and  Usher  1B,  hearing  impairment  in  DFNA11  families  is  initially  mild
and shows only slow progression. The cochleovestibular phenotype was
comparable in all the DFNA11 families, except for two. Family members with the
Gly722Arg mutation did not have any vestibular problems133, while the family
with the Ala230Val substitution had more profound hearing impairment and all
three patients investigated had vestibular areflexia; the youngest patient was 11
years old.135 The clinical and genetic data are listed in Table 4.
DFNA9 and DFNA11 are the only types of autosomal dominant hearing
impairment known to be associated with vestibular dysfunction. However,
Ishiyama et al. described a new audiovestibular syndrome with a dominant
pattern of inheritance, but no mutations in the COCH or MYO7A gene.236 Hearing
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impairment started primarily at the high frequencies in the fourth decade, while
the onset of vestibular dysfunction occurred early in the seventh decade.
Subclinical retinal dysfunction was present exclusively in the DFNA11 family
with the Asn458Ile mutation. Abnormalities were found using Goldmann peri-
metry, electro-oculography and electroretinography. These findings suggested
subtle defects in the retinal pigment epithelial cells and photoreceptor cells, in
which myosin VIIa was expressed.134
Table 4. Phenotype and genotype of DFNA11
l.f., low frequency; y, years.
Genetic aspects
In 1996, DFNA11 was localized to chromosome 11q13.5.8 DFNA11  is  caused  by
mutations in MYO7A. This gene is also involved in autosomal recessive hearing
impairment (DFNB2),10,11 Usher syndrome type 1B (USH1B)12 and atypical Usher
syndrome.13,14 Mutations in other unconventional myosin genes are also
responsible for different types of hereditary hearing impairment, such as MYO1A
in DFNA48, MYO3A in DFNB30, MYO6 in DFNA22 and DFNB37 and MYO15A in
DFNB3 (Hereditary Hearing Loss Homepage.) These different interactions
demonstrate the important function of myosins in the inner ear. Myosin VIIa
consists  of  a  highly  conserved  motor  domain  with  actin  and  ATP-binding  sites,
five IQ regions that are expected to bind calmodulin137,237 and a long tail. The tail
contains a coiled-coil dimerization domain and two MyTH4 FERM repeats,
separated by a poorly conserved SH3 domain.238-241 Although the function of the
MyTH4 domains is not yet understood, the FERM domains are involved in
membrane attachment.240
Origin Exon Amino
Acid
Change
Affected
Domain
Hearing
Onset
Hearing Impairment Vestibular Dysfunction
Subjective   Objective
Retinal
Involvement
Italy 7 Ala230Val motor
domain
6 y Moderate-profound,
flat
minor all areflexia absent
Netherlands 13 Asn458Ile motor
domain
4-43 y l.f.?flat?downsloping 4 out of 6 4 out of 6 subclinical
US 17 Gly722Arg motor
domain
20-30 y l.f.?flat?downsloping absent not
available
absent
Germany 21 Arg853Cys IQ5
domain
childhood not available not
available
1 out of 5 absent
Japan 22 Ala886_
Lys888del
coiled
coil
region
12-16 y flat?  downsloping absent 3 out of 5 absent
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Myosin VIIa is expressed exclusively in epithelial tissues, principally those that
contain cilia or microvilli, such as the inner ear, retina, testis, lung, kidney, liver,
olfactory epithelium and intestine.242-244 In  the  cochlea,  myosin VIIa  expression is
more prominent in inner hair cells than in outer hair cells. Localization is mainly
in  the  stereocilia,  but  it  also  occurs  in  the  cell  bodies,  the  cuticular  plate,  the
pericuticular necklace and the synaptic region.239,242,244-246  In addition, myosin VIIa
is present in type I and type II hair cells of the utricle and semicircular canals.242 In
the eye, it is highly expressed in the apical microvilli-like processes of retinal
pigment epithelial cells and in the connecting cilium and photoreceptor synapses
of the photoreceptor cells.244-247
Mutations in DFNA11 cause structural changes in either the motor domain or the
IQ5 domain and lead to dysfunctional ATP/ADP binding, impairment of the
power-stroke or the molecular switch.136,137 It has been suggested that MYO7A
mutations have a dominant negative effect due to incorrect dimerization in the
family with the Ala886_Lys888del mutation,132 or due to correct dimerization with
wild-type proteins that impair protein function in the families with Asn458Ile and
Arg853Cys mutations.136,137  Clinical severity varied between two branches of the
family described by Street et al., which suggests the presence of a genetic
modifier.133
The function of myosin VIIa
Myosin VIIa is a membrane-associated motor molecule that moves along actin
filaments by means of actin-activated ATP-ase activity. Owing to its
spatiotemporal expression pattern and binding of the tail domain to a number of
ligands,248,249 it  is  thought  to  be  involved  in  several  processes,  such  as  the
development, differentiation and organization of the cochlear hair cell
stereocilia.250-252
Part of the Usher syndrome type 1 protein network is formed by myosin VIIa.
This protein is present in the developing hair bundles, beneath the cuticular plate
of the cochlear and vestibular hair cells and in the synaptic region.249 The protein
network is important to development, differentiation, and cohesion of the
stereocilia during hair cell maturation.251,252 In mature hair cells, the Usher protein
network may contribute to mechano-electrical transduction processes in the
stereocilia241,251-254 and it may also be involved in the organization and/or function
of cochlear hair cells and retinal photoreceptor synapses.252,255
In the eye, myosin VIIa is involved in the migration of melanosomes in the retinal
pigment epithelial cells,256-258 in the phagocytosis of photoreceptor outer segment
tips by retinal pigment epithelial cells259 and  in  the  ciliary  transport  of  opsin  in
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photoreceptor cells.260 The latter is demonstrated by abnormal opsin accumulation
in the membrane of the connected cilium in Myo7a-deficient shaker-1 mice.260
The transmembrane protein vezatin is a ubiquitous protein of adherence cell-cell
junctions  and is  attached to  cadherin  by myosin VIIa.  Myosin VIIa  is  thought  to
link the actin cytoskeleton to adherence junctions between hair cells and
supporting cells to consolidate cell-cell adhesion. The interaction of myosin VIIa
with vezatin at the ankle links attachment sites suggests that there is a tension
force between the stereocilia that strengthens the cohesion of the hair bundles.241,261
In conformity with these notions, shaker-1 mutant  mice  with  a  null  mutation  in
Myo7a showed disorganization and disruption of the hair bundles during
development and in the end loss of the stereocilia.250,262 An  autosomal  dominant
mutation was found in Myo7a in headbanger mice that caused low-frequency
hearing loss and vestibular dysfunction. Scanning electron microscopy revealed
abnormal stereocilia bundle development from an early age that was more
prominent in the apex than in the base of the cochlea. Therefore, this “headbanger
gene” was also found to be involved in stereocilia development and
preservation.263 Further studies on these mouse models are necessary to gain
greater understanding of the effects of the different mutations in DFNA11 on the
function of myosin VIIa.
Aims of this study
The core objective of this thesis was to generate new clinical knowledge from a
number of families with a non-syndromic autosomal dominant type of hearing
loss by performing thorough phenotypic analyses in relation to the genotype in
families with DFNA5, DFNA9 and DFNA11. Audiometric and vestibular data
were collected from the families to outline and analyse the cochlear and vestibular
phenotype. Blood samples were taken for linkage and mutation analyses to
identify the genetic defect. Additionally, other clinical aspects were examined,
such  as  speech  recognition  scores.  It  also  proved  worthwhile  to  include
ophthalmologic examinations to obtain data on subclinical features in two of the
DFNA types included in this thesis.
Research into hereditary hearing loss has been complicated by the small numbers
of  patients  with  each  type,  the  inaccessibility  of  the  inner  ear  to  biopsy  and  the
lack of representative animal models for many types of hereditary hearing loss.
Due to the high degree of genetic heterogeneity and the low incidence of the
genetic subtypes, diagnostic screening will be too expensive and time-consuming.
Therefore, it is important to study phenotype-genotype correlations in order to
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make more specific diagnoses. The major goal is to create phenotypic criteria,
such as the ARTA, to enable differentiation between subgroups of non-syndromic
hearing impairment. Routine DNA diagnostics are available for the more frequent
types of hereditary hearing impairment, such as DFNA9. DNA diagnostics are
also available for the MYO7A gene,  in  the  form  of  the  Usher  microarray  to  test
known mutations. Knowledge about the different genotypes and the genotype-
phenotype  correlations  is  important  to  genetic  counselling  and  provides  insight
into the molecular biology and function of the inner ear on the basis of the gene
product. Greater understanding will contribute to the development of preventive
and therapeutic strategies for hearing impairment.
Aims of the study
1. To evaluate the phenotype and genotype of a DFNA5 family and to compare
the phenotypic features to the data on the original DFNA5 family.
2. To evaluate and analyse audiometric and electronystagmographic data
obtained from many carriers of the Pro51Ser mutation in the COCH gene.
3. To describe peculiar vertical corneal striae in families with DFNA9, to test
whether there is an association between these vertical corneal striae and
COCH gene mutations and to formulate a plausible causative relation.
4. To  outline  the  cochleovestibular  phenotype  in  a  DFNA11  family  and  to
compare the data to the phenotypes of three other DFNA11 families.
5. To describe subclinical retinal abnormalities that are unique to DFNA11.
The results of this study are described in five chapters. Chapter 2 provides clinical
and genetic descriptions of a family with DFNA5. Chapter 3 focuses  closely  on
cochleovestibular dysfunction in DFNA9. In Chapter 3.1 an in-depth analysis is
reported on many individuals with the Pro51Ser mutation. Chapter 3.2 describes
the  vertical  corneal  striae  in  patients  with  DFNA9. Chapter 4 reports the
cochleovestibular and retinal features in a DFNA11 family. Chapter 5 summarises
all  the  studies  and  includes  the  general  conclusions  and  discussion.  A  Dutch
translation of chapter 5 is given in Chapter 6.
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Abstract
A novel DFNA5 mutation was found in a Dutch family, of which 37 members
were examined. A nucleotide substitution was identified in the splice-acceptor site
of intron 7, leading to skipping of exon 8 in part of the transcripts. The mutation
was found in 18 individuals. Sensorineural hearing impairment was non-
syndromic and symmetric. In early life, presumably congenital, hearing
impairment amounted to 30 dB in the high frequencies. Progression was most
pronounced at 1 kHz (1.8 dB/y). Speech recognition was relatively good with a
phoneme score of about 50% at age 70. Onset age was 37 years and recognition
deteriorated by 1.3% per year. The recognition score deteriorated by 1.0% per dB
threshold increase from a mean pure tone average (PTA 1, 2, 4 kHz) of 63 dB onwards.
Vestibular function was generally normal. The second mutation identified in the
DFNA5 gene results in hearing impairment, similar to that in the original DFNA5
family  in  terms  of  pure  tone  thresholds,  but  with  more  favourable  speech
recognition.
Introduction
Since the early nineties, gene linkage and mutation analysis have been applied to
increase our knowledge of hereditary non-syndromic hearing impairment. At the
moment about 75 genetically different types of non-syndromic hearing
impairment have been identified.1 Knowledge of hereditary hearing impairment
at a molecular level is still  limited, but can be enhanced by studies on genotype-
phenotype correlations in families with hearing impairment.2 This is especially
true for autosomal dominant types, which display the largest phenotypic
variation.  The  results  of  such  family  studies  are  also  of  value  for  genetic
counselling purposes.
Up to now, only one DFNA5 family has been described.3-9 In this family, non-
syndromic symmetric hearing impairment was most severe at the high
frequencies and progression was most distinct in the first three decades of life. In
1995 the responsible gene was localized to a region on chromosome 7p15. The
locus was designated DFNA5.10 After sequencing of the DFNA5 gene, a complex
insertion/deletion mutation was found in intron 7, causing skipping of exon 8 and
leading to premature termination of the encoded protein. As there was no
indication for its function, the gene was called DFNA5 by default.11 The DFNA5
protein is not homologous to any other human protein described up to now. Also
no  information  is  available  about  the  structure  or  the  subcellular  localization  of
the protein.
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In this report we describe a second mutation in the DFNA5 gene in a Dutch family
with autosomal dominant sensorineural hearing impairment. A nucleotide
substitution  was  identified  in  the  splice-acceptor  site  of  intron  7,  which  leads  to
alternative  splicing.  This  results  in  skipping  of  exon  8  in  part  of  the  transcripts.
Pure tone and speech audiometric data were analysed and compared to the
results in the previously described DFNA5 family.12 Although a larger part of the
transcripts is normal in comparison to the original DFNA5 family, the severity of
hearing impairment is fairly similar in terms of pure tone hearing thresholds.
Patients and methods
A five-generation pedigree was established for the present family (W00-212).
Thirty-seven family members participated in this study. The medical history was
taken and otologic examination was performed. Attention was paid to the
presence of any syndromic features. Non-hereditary causes of hearing loss were
excluded and written informed consent was obtained. All individuals included in
this study underwent pure tone audiometry; speech audiometry was performed
in affected persons only. Vestibular function was tested in six cases. One affected
person underwent computerized tomography of the temporal bones. Blood
samples were obtained for linkage analysis from 18 presumably affected family
members and 19 presumably unaffected persons.
Audiometric analysis
Pure tone and speech audiometry were performed in a sound treated room,
conforming to the International Standards Organization (ISO) standards.13,14 The
individual 95th percentile threshold values of presbyacusis (P95) in relation to the
patient’s sex and age were derived for each frequency using the ISO 7029
method.15 Persons were considered affected if the best hearing ear showed
thresholds beyond the P95. Mean binaural  threshold levels  were  used to  perform
longitudinal regression analyses. Analysis of covariance (ANCOVA, Prism PC
version 3.02; GraphPad, San Diego CA, USA) was performed to compare between
slopes and intercepts of the regression lines pertaining to individual
measurements per frequency. Where pooled regression was inappropriate, the
median slope (called annual threshold deterioration, ATD, expressed in dB/year)
and intercept were calculated, following inspection of the corresponding
frequency  distributions.  Outlying  values  were  excluded,  if  necessary.  The  lines
defined by the combination of the slope and intercept values thus obtained were
called trend lines. These lines were used to construct Age Related Typical
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Audiograms (ARTA). To compare the audiological data of the original12 and the
present DFNA5 family, we transformed the ARTA into a one-dimensional
threshold features array, which can be used for chi-square analysis, as previously
described.2
Speech audiometry
Speech audiometry was performed, using standard monosyllabic Dutch word
lists. The maximum monaural phoneme score (% correct recognition) was derived
from a performance versus intensity plot. Cross-sectional binaural mean phoneme
recognition scores were plotted for all mutation carriers against age and binaural
mean PTA 1,2,4 kHz (pure tone average in dB hearing level). Non-linear regression
analysis was used to fit sigmoidal dose-response curves with variable slope, as
previously described.16 Outlying  values  were  excluded,  if  necessary.  The  age  of
onset and onset level were defined at a maximum phoneme recognition score of
90% in the performance versus age and performance versus impairment plots.
The slope was called deterioration rate in the performance versus age plot,
whereas it was called deterioration gradient in the performance versus
impairment plot. To simplify the results and allow for additional testing, “local
average” slope (i.e. on a linear scale) for X > X90 (X is either age or PTA level) was
obtained by fitting a straight line as previously described,17 using a non-linear
method to estimate X90.18 Student’s t test (with Welch correction if significantly
unequal variance was detected by Bartlett’s test) was employed to test age of
onset, deterioration rate, onset level or deterioration gradient between the present
and the original DFNA5 family.18
Linkage analysis
DNA was isolated from peripheral blood according to Miller et al.19 Analysis of
the micro satellite markers was performed as described by Kremer et al.20 Two-
point lod scores were calculated with the MLINK subroutine of the LINKAGE
package version 5.1.21-23 A penetrance of 0.95, a disease allele frequency of 0.0001
and a phenocopy rate of 0.001 were assumed for the calculations.
Mutation analysis
Amplification of the protein-coding region from chromosomal DNA was
performed using standard PCR conditions. Primer sequences have been described
by van Laer et al.,24 except for amplification of exon 9 for which we used 5’-
GGTCCCACCTGGGAGGTTGC-3’ and 5’-CTGTGACTGTGATTTTTCTCTCC-3’.
Prior  to  sequencing,  PCR  fragments  were  purified  with  the  QIAquick  gel
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extraction kit (Qiagen). Sequence analysis was performed using the ABI PRISM
Big Dye Terminator cycle sequencing V2.0 ready reaction kit and an ABI PRISM
3700 DNA analyser (Applied Bio systems). For testing the segregation of the
mutation  in  the  family  genomic  DNA  was  amplified  with  the  primers  5´-
GTCTCCAGCTGTGTCATGACC-3´and 5´-CCATTTCTTTCATTTTCTTTTCTCC-
3´. PCR fragments were digested with RsaI (Invitrogen) and separated on an
agarose gel (Seakem agarose, FMC).
Reverse transcriptase polymerase chain reaction
Messenger RNA of lymphoblastoid cells cultured under standard conditions was
isolated according to the RNA-Bee (Campro Scientific) protocol.
To establish the effect of nonsense mediated RNA decay (NMD), lymphoblastoid
cells were treated with cycloheximide (100µg/mL cell culture medium) for 4.5
hours. For the initial testing of skipping of exon 8 and detection of other
alternative  splicing  products,  cDNA  was  synthesized  by  random  priming  with
MMLV reverse transcriptase (Invitrogen). Subsequently PCR was performed with
the primers 5´-CCTGAGCCACAACAGACAGC-3´ in exon 7 and 5´-
GGCACAGTGTGGGAATGATCTG-3´ in exon 9 and fragments were analysed on
agarose gel. For the detection of alternative splicing in other parts of the mRNA,
the following primers were used: 5´-AGAGGCCCCGACATCTCC-3´ in exon 1, 5´-
TCGACCTGCATGTGCTCAG-3´ in exon 4, 5´-GGTGCTGGAAGGAAGGAATG-
3´ in exon 4, 5´-CAAATAGGACCGCCTGGAAG-3´ in exon 7, 5´-
TCTGCTGGGCACTTGCTG-3´ in exon 9 and 5´-
TCATCATGCAAAATGTCACCAC-3´ in exon 10. For comparison of the ratio
between the normal and the short DFNA5 mRNA,  cDNA  synthesis  was
performed with the One-Step RT-PCR kit (Qiagen). The 32P-labelled primers given
above for testing of exon 8 skipping were used and 25 cycles of PCR were
performed. After denaturation, fragments were separated on a denaturing
acrylamide gel. Phospo-imaging was performed using the Gs-363 molecular
imaging system (Biorad). The data were analysed and the ratios between normal
and short mRNA were determined with the molecular analyst software, version
1.5 (Biorad). As control samples for RT-PCR, mRNA was isolated from
lymphoblastoid cells of 22 normal-hearing individuals. One individual was 15
years old, all others were between 20 and 83 years old.
Southern blot analysis
Chromosomal DNA (about 8 µg per lane) was digested with MspI, EcoRI and TaqI
and separated on a 0.8% agarose gel (Seakem agarose, FMC) and blotted onto
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GeneScreen  plus  (NEN  Life  Science  Products)  by  a  standard  dry  blot  transfer
method.  As  probe,  40  ng  of  a  cDNA  encompassing  the  complete  coding  region
was labelled with ?[32P]dCTP by random primer extension and hybridized under
standard conditions.
Results
The pedigree (Figure 1) comprised 27 affected family members, 18 of whom were
still  alive  and  participated  in  this  study.  The  pattern  of  inheritance  is  clearly
autosomal dominant.
Figure 1. Pedigree of family W00-212 and genotypic data for markers flanking the DFNA5
gene, listed in centromere-to-telomere order. The most likely haplotypes are shown. A
bar indicates the haplotype that is associated with the affected status. The marker order is
in agreement with the most recent freeze (June 2002) of the Human Genome Working
Draft (http://genome.ucse.edu). Men are indicated with squares, women are indicated
with circles and filled symbols indicate affected persons. The proband is indicated with
an arrow. Haplotype reconstruction for the individuals III:2 and III:3 suggests the
presence of five alleles. However, assuming one allele change for marker D7S2493 for
either individual IV:3 or IV:6 can explain this.
Phenotype and genotype of a novel DFNA5 family
56
V17 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
30.52 y
30
V9 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
13.38 y
27.85 y
32.68 y
12
33
10,39 y
12,10 y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V9 L
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V47 LV47 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
10.32 y
12.24 y
10.08 y
12.59 y
13.13 y
14.73 y
Nl. vestibular
responses
15
10
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V17 L
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V30 LV30 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
34.13 y
35
36.72 y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V41 LV41 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
24.26 y
26.65 y
25
Hyperactive
vestibular
responses
V12 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
31.43 y
31
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V12 L
A B
V15 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
32.17 y
36.91 y
34
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V15 L
C
V21 R
0.25 0.5 1 2 4 8
0
20
40
60
80
100
120
12,55 y
20.47 y
26.17 y
32.67 y
36.89 y
38.49 y
-10
dB
kHz
12
38
Surgery
?
?
?
??
?
0.25 0.5 1 2 4 8
0
20
40
60
80
100
120
-10
dB
kHz
?
?
?
?
V21 L
D
E
G
F
H
V28 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
31.68 y
32.68 y
33.90 y
35.71 y
39.83 y
30
40 Nl. vestibular
responses
30.15 y 0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V28 L V6 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
31.45 y
35.67 y
38.59 y
39.36 y
39.97 y
31
40
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V6 L
I J
Chapter 2.1
57
IV22 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
36.54 y
35.98 y
40.36 y
44.78 y
49.54 y
52.28 y
53.62 y
36
54
Nl. vestibular
responses?
IV13 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
34.92 y
61.46 y
62.60 y
35
63
?
?
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
?
?
?
?
IV13 L
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
?
IV29 LIV29 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
24
48
Nl. vestibular
responses ?
34.22 y
36.19 y
38.16 y
40.42 y
41.46 y
44.49 y
46.78 y
48.38 y
23.97 y
30.47 y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
?
IV22 L
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
?
? ?
IV3 LIV3 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
56.38 y
63.00 y
60
??
? ?
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
IV25 LIV25 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
42.00 y
36.00 y
37.00 y
45.00 y
47.00 y
51.29 y
36
51
Nl. vestibular
responses
IV6 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
46.30 y
56.60 y
60.07 y
46
60
?
?
?
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
? ?
?
?
?
?
?
IV6 L
K L
IV1 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
28.74 y
30.95 y
46.98 y
62.16 y
66.21 y
66.43 y
?
29
66
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
?
IV1 L
M
III15 R
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
68.65 y
68
? ?
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
? ?
III15 L
N
O
Q
P
R
Figure 2. Audiograms of the 18 affected family members. Nl = normal. The dotted lines
represent the predicted thresholds at the ages specified, as derived from the ARTA. The
results of the six vestibulo-ocular function tests are also indicated.
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Affected persons showed no evidence of other causes of hearing impairment than
otitis in the past, except for case V:21, who had a cholesteatoma in the right ear at
14 years of age that required surgery. The data for the right ear in this individual
were therefore excluded from the present analysis. The first symptoms of hearing
impairment were reported at ages ranging from 0 to 40 years. Vestibular
symptoms were not reported. Otoscopy was generally normal. Pure tone
audiograms (Figure 2) showed a so-called Z-shape curve; predominantly high
frequency hearing loss with a large drop for the mid-frequencies and relatively
sparing of the lower frequencies. The audiograms were fairly symmetric, except
for cases V:21 and V:30.
Audiometric analysis
All available data, combining individual longitudinal (11 cases) and single
snapshot (7 cases) measurements are shown in Figure 3. As ANCOVA indicated
that pooling of regression lines was not allowed for any frequency, the trend lines
were  derived.  At  each  frequency,  it  was  checked  that  fairly  similar  numbers  of
individuals were represented by threshold values – either pertaining to
longitudinal or snapshot observations - above and below the trend line. The ATD
increased from 0.7 dB/year at 0.25 kHz to 1.8 dB/year at 1 kHz and then decreased
to 1.2 dB/year at 4-8 kHz.
The constructed ARTA (Figure 4) show a configuration with congenital high
frequency hearing impairment of about 30 dB and progression that was most
pronounced at 0.5 and 1 kHz. To check whether the constructed ARTA was
reliable, we plotted the thresholds predicted for minimum and maximum age,
derived from the ARTA, in the original audiograms (Figure 2, dotted lines). This
highlighted threshold variability, especially in the younger individuals, who
seemed to be more severely affected than was indicated by their expected
audiograms.  Attempts  to  improve  prediction  for  the  younger  patients  only
succeeded at the cost of the quality of prediction in the remaining cases and were
therefore abandoned.
In Figure 4, the ARTA published for the original DFNA5 family12 is illustrated, in
juxtaposition with the ARTA derived for the present family. For both families, we
created a threshold features array as described elsewhere.2 A chi-square  test  did
not detect a significant difference between the families, although in the first four
decades the ARTA of the present family exhibited better thresholds at the speech
frequencies.
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Figure 3. Longitudinal analysis (binaural air conduction threshold). Threshold data (in dB
hearing level) versus age (in years) for the frequencies from 0.25 to 8 kHz combining
individual longitudinal data (open circles) with connecting hairlines and single snapshot
measurements (filled circles) of the 18 mutation carriers. The regression lines fitted to the
individual longitudinal measurements are included (a bold line indicates significant
progression). The dotted line pertains to the trend line derived for the ensemble of these
data points (see text). Slopes and intercepts are indicated in bold.
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We checked for the presence of phenotypic differences related to gender since the
expression of DFNA5, also known as ICERE-1, is higher in estrogen-receptor-
negative than in estrogen-receptor-positive breast carcinomas;25 none were found.
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Figure 4. ARTA of the original and the present DFNA5 family from birth to the 7th
decade. Italics indicate age (years) in decade steps.
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Figure 5. Cross-sectional binaural mean speech recognition scores at last visit against age
(A) and PTA at 1, 2 and 4 kHz (B). The continuous curve was fitted using a non-linear
equation. A straight line (dashed) approximated the relevant part of this curve, see
methods. The onset age and onset level were derived, using the non-linear curve.
Speech recognition
Speech recognition was relatively good, with scores still better than 50% at the age
of 70. The recognition score (Figure 5A) declined substantially from onset at the
age of 37 with a deterioration rate of 1.3% per year (Table 1). The 90% recognition
score was found at a PTA level of 63 dB hearing level and deteriorated by about
1.0 % per dB (Figure 5B).
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Table 1. Speech recognition scores
Present
DFNA5
Original
DFNA5
DFNA2 DFNA9
Age, years
n 12 33 43 41
Onset age 38 (28-49)     S 16 (10-22) 34 43
SE 5 3
Det. Rate 1.3 (0.5-2.0)  NS 0.7 (0.4-0.9) 0.3 1.8
SE 0.3 0.1
PTA, dB
n 11 33 42 41
Onset level 66 (53-80)     S 41 (31-52) 65 46
SE 6 5
Det. gradient 1.0 (0.5-1.6)  S 0.4 (0.3-0.6) 0.5 1.2
SE 0.3 0.1
Onset age (years), onset level (dB), deterioration (det.) rate (% per year) and deterioration gradient (% per dB)
are shown for the original and the present DFNA5 families. Age and PTA indicate 95% confidence intervals.
n = number of cases, SE = standard error, S = significantly different, NS = not significantly different. The data
of  the  present  family  shown  in  the  table  were  derived  from  the  linear  curve  that  approximates  the  most
relevant  part  of  the  continuous  curve.  The  two  columns  on  the  right  show  reference  data  of  DFNA2  and
DFNA9.
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Figure 6. Comparison of performance versus age (A) and performance versus impairment
level (B) plots pertaining to speech recognition scores of the present (A5new, dashed line)
and the original (A5old, dotted line) DFNA5 patients. Linear plots (X > X90) for the scores of
DFNA2 (A2) and DFNA9 (A9) patients are included for comparison (see text).
The present findings were compared to and tested against the previously reported
results for the original DFNA5 family.18 It appeared that onset age, onset level and
deterioration gradient were significantly higher in the present family (Table 1,
Figure 6). The deterioration rate of the present family, although substantially
higher,  did not  differ  significantly  from the  one derived for  the  original  DFNA5
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family. Figure 6 demonstrates that at an age of < 65 years, our patients had better
recognition scores than the patients from the original family, which could also be
explained by their more favourable thresholds in the speech frequencies in the
first four decades of life (Figure 4). Patients from the two DFNA5 families tended
to develop similar poor phoneme scores at an advanced age (Figure 6A) and
around a PTA level of about 85 dB at a score of about 75% (Figure 6B).
Remarkably, Figure 6B suggests the scores to diverge at higher PTA levels, with
relatively better performance in the original DFNA5 family.18
Vestibular function tests and computerized tomography
Although no vestibular problems appeared to be present in this family, vestibular
function was tested in six cases. Electronystagmography was normal in five cases
(IV:22, IV:25, IV:29, V:28 and V:47) and revealed a hyperactive vestibulo-ocular
reflex in one individual (V:41). Computerized tomography (case IV:22) showed a
normal temporal bone configuration.
Linkage analysis
Due to the similarity of the type of hearing loss in the present family as compared
to that in the DFNA5 family described previously, linkage studies were initiated
with markers flanking the DFNA5 gene. The markers D7S629 and D7S673 are
located telomeric to the DFNA5 gene at 7p15.3 and D7S2493 and D7S529 are
derived from the region centromeric to the gene. All markers are located within a
distance of 2.5 cM from the gene according to the Généthon genetic map.26 All
affected individuals were included in the linkage analysis, as well as non-affected
individuals from the age of 30 years onwards. As already suggested by the type of
hearing loss, there was cosegregation of the disorder and a specific haplotype in
the DFNA5 interval (Figure 1). A maximum lod score of 6.82 was calculated for
marker D7S673. The maximum lod score for markers D7S629, D7S2493 and
D7S529 were 3.85, 2.34 and 5.09 respectively.
Mutation analysis
For two affected family members the coding region and the exon-intron
boundaries of the DFNA5 gene were analysed for the presence of a mutation by
DNA sequencing. When compared to the published sequence, two changes were
found. The first change was a C to G transversion in the splice acceptor site of
intron 7 at position –6, which was heterozygously present. The second change was
a c.1200 G>A transition in exon 9 (1257 G>A),24 which was homozygously present.
This was a silent mutation that was also seen homozygously in patients from the
Chapter 2.1
63
original  DFNA5  family  and  the  majority  of  the  control  individuals.  The  C  to  G
transversion created an RsaI restriction site. The cosegregation of the mutation in
the  family  could  therefore  be  shown  by  restriction  digestion  of  a  265-bp  PCR
fragment encompassing the mutated splice site, resulting in two fragments of 226
bp  and  39  bp  in  length  (Figure  7).  The  mutation  was  not  present  in  100  control
individuals.
No deletions in any part of the gene could be detected by probing a Southern blot
containing genomic DNA of two patients (III:15 and IV:1) and two control
individuals with cDNA representing the entire protein-coding region (data not
shown).
III:15   IV:1   IV:2   IV:3    IV:4   IV:5    IV:6   IV:12  IV:13  IV:15 IV:16  IV:19  IV:21 IV:22 IV:23  IV:25  IV:27 IV:29
265 bp
226 bp
IV:30  IV:31 IV:33  IV:35   V:1    V:4     V:6     V:7     V:9  V:12   V:13   V:15  V:17   V:19   V:21   V:28   V:30   V:41  V:47
265 bp
226 bp
TCCCTGCCCTACAG
TCCCTGCCGTACAG
TGC
TGC
RsaI
exon 8intron 7A
B
Figure 7. Restriction analysis. A. Sequence of the boundary of intron 7 and exon 8 of the
DFNA5 gene, showing that the mutation creates an RsaI restriction site. B. Restriction
digestion with RsaI in 18 affected and 19 non-affected family members. The 265 bp
fragment represents the wild type allele, the 226-bp fragment the mutant allele.
Effect of the splice site mutation on splicing efficiency
Although the detected mutation in the splice acceptor site of intron 7 was not
predicted27 to lead to a reduced splicing efficiency (86.25 versus 85.00), mRNA
derived  from  cultured  lymphoblastoid  cells  was  analysed  for  the  presence  of
alternative splicing products. RT-PCR with primers located in exon 7 and exon 9
resulted in a fragment of 152 bp, which indicates skipping of exon 8 (Figure 8A).
The absence of exon 8 in the fragment was confirmed by sequence analysis.
Skipping of exon 8 causes a frame shift at amino acid 330. This leads to 41
aberrant codons followed by a premature stopcodon. The amount of the short
PCR  product  found  in  this  study  was  lower  than  the  amount  found  in  patients
from  the  original  DFNA5  family,  in  which  the  mutation  also  affects  splicing  of
intron 7 leading to skipping of exon 8 (Figure 8A). 11 A variable but low amount of
the PCR fragment representing the alternatively spliced mRNA was also seen in
some control individuals. Therefore, 22 control individuals, two patients of the
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present  family  and  two  patients  of  the  original  DFNA5  family  were  compared
with  regard  to  the  ratio  between  RT-PCR  products  with  and  without  exon  8  by
phospho-imaging (Figure 8B). One control measurement was detected as an
outlier because the background signal was higher than the signal from the
alternatively spliced mRNA resulting in a negative measured ratio. Therefore this
measurement was excluded from the analysis.
For the remaining control measurements, the mean was 0.034 and SD 0.024.
Ninety-five % tolerance limits, according to t statistics ranged from –0.017 to
0.084. All DFNA5 patients had values above the upper tolerance limit. Skipping of
exon 8 was therefore statistically significantly more frequent in patients of the
present and the original family as compared to control individuals.
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Figure 8. (A) Aberrant splicing of exon 8 of the DFNA5 gene. Two affected persons from
the original DFNA5 family (A5old), two affected persons from the present DFNA5 family
(A5new) and 8 control individuals (controls) are shown. The wild type splice product is 345
bp long; the aberrant splice product in which exon 8 is skipped is 152 bp long. (B) Ratios
of mutant versus wild type (wt) cDNA of two patients of the present family (A5new), two
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patients of the original DFNA5 family (A5old)  and 22  control  individuals  (controls).  The
inset shows part of the data on a different scale.
Student’s t test detected a significant difference (P=0.003) between the original
DFNA5 patients (mean 4.34) and the present DFNA5 patients (mean 0.365).
Consequently,  splicing  in  the  patients  of  the  present  family  was  less  severely
disturbed  than  in  the  original  DFNA5  family.  The  presence  of  the  C-to-G
transversion in the splice acceptor site of intron 7 at position –6 was excluded in
the 22 normal hearing control individuals by restriction digestion with RsaI and
DNA sequencing.
To  exclude  that  the  difference  in  the  amount  of  the  long  and  the  short  splice
product was a result of preferential degradation of the short splice form by NMD,
we used the chemical cycloheximide to inhibit NMD in lymphoblastoid cell
cultures of two affected individuals from the present family. We found a 1.36-fold
increase of the average ratio when cycloheximide was added (data not shown).
Because the amounts of long as well as short splice product were increased after
treatment, 1.33- and 1.80-fold respectively, the increased ratio could only be
attributed to the presence of an increased amount of short splice product.
To exclude additional intronic mutations that affect correct splicing of the DFNA5
mRNA,  RT-PCR  was  performed  with  mRNA  derived  from  cultured
lymphoblastoid  cells  of  two  patients  and  two  control  individuals.  Six  primer
combinations were used, which amplify overlapping cDNA fragments, covering
the entire coding region. There were no indications for additional alternative
splicing (data not shown).
Discussion
We report the second family with a mutation in the DFNA5 gene associated with
hearing loss. Noticeable is the fact that the mutation in both families influences
the splicing process resulting in skipping of exon 8, however to a different extent.
The relatively fast elucidation of the molecular defect in this second DFNA5
family, based on a comparison of the type of hearing loss with that of a genetically
elucidated type, illustrates the value of a detailed analysis of hearing loss in
families.
Sensorineural hearing impairment in the present family was non-syndromic and
symmetric with progression of 0.7-1.8 dB/year, depending on the frequency.
Progression  was  fairly  constant,  in  contrast  with  the  original  family,  in  which
there was more rapid progression in the first four decades than at more advanced
ages, especially in the high frequencies (about 1 dB/year at 0.25-1 kHz and 1-4
dB/year at 2-8 kHz).12 The  ARTA,  however,  were  not  significantly  different.  A
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large variation in audiogram types was found, which was also reported in the
original family. There was more severe hearing loss in the younger individuals
than was predicted following the present procedures.
Speech recognition scores were relatively good with an onset age of 37 years and
deterioration rate of 1.3% per year. Recognition scores decreased by 1.0% per dB
threshold increase  from a  mean PTA1,  2,  4  kHz of  63  dB onwards.  The difference  in
speech recognition between both families might be explained by the more
favourable thresholds in the speech frequencies in the first four decades of life,
demonstrated by the ARTA of the present family.
Table 1 and Figure 6 include data derived from previous reports on DFNA2 and
DFNA9.16 Straight  lines  were  fitted  for  X  >  X90 to approximate the regression
curves. The original DFNA5 patients tended to show similar phoneme scores as
the DFNA9 patients, only at a more advanced age. The present DFNA5 patients
showed this  similarity  already from a  younger  age onwards.  At  a  given level  of
hearing impairment, DFNA5 patients of both families generally showed
recognition scores that were better than those of DFNA9 patients, but worse than
those  of  DFNA2  patients.  As  previously  described,16 the high-frequency sensori-
neural hearing impairment of DFNA2 may be attributed to lack of expression of
potassium channels, especially in the inner hair cells of the lower turns in the
cochlea. Relatively better speech recognition in DFNA2 was explained by relative
sparing of outer hair cell function in this region preserving pre-amplification and
fine-tuning mechanisms. The relatively good speech recognition performance in
DFNA5 patients might be explained in a similar way.
The  similarities  in  the  type  of  hearing  loss  and  a  comparable  effect  of  the
mutations, namely skipping of exon 8 in both the present and the original DFNA5
family, indicate that the mutation in the present family indeed is the disease-
causing genetic defect. Also, despite  one silent mutation, no other mutations were
found in the DFNA5 gene in the present family. Although the transcript without
exon 8 was also seen in control individuals, the relative amount was statistically
significantly higher in the two patients from the present family than in the control
individuals. Also, we have to note that the effect of the mutation on splicing might
be different in the inner ear compared to lymphoblastoid cell lines. The 1200 G>A
polymorphism has no major influence on the splicing efficiency of exon 8, because
the disease-causing mutation in the present and the original family co-segregates
with an A at position 1200. Also, the majority of the controls were homozygous A.
Even though our results show that the ratio between the long and short splice
form  increases  after  treatment  with  cycloheximide,  the  lower  amount  of  short
splice  product  as  compared  to  the  amount  of  long  splice  product  in  the  present
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family remains, indicating that this difference is not a result of NMD. Also, the
low amount of short mRNA in the present family as compared to the previously
described family cannot be explained by a higher rate of NMD in the present
family.
The  relatively  low  amount  of  the  short  transcript  in  the  present  family  suggests
that not haploinsufficiency but a dominant negative effect of the mutant protein
causes the hearing loss, which might be attributed to the relatively large stretch of
41 aberrant amino acids. Since the alternative splicing product is also seen in a
variable but lower ratio to the normal mRNA in controls, there might be a critical
threshold for the aberrant protein above which it becomes pathogenic. This is
underlined by the fact that the mutations in the only two DFNA5 families known
so far have the same effect on the mRNA and the putative protein but affect a
different amount of the transcript. Unfortunately, nothing is known about either
the wild type or the short protein. Both proteins have very different C termini and
neither have similarity with any other protein or protein domain. Whether the
differences in speech recognition between the two families are due to the different
ratios of normal versus short protein remains to be elucidated. One might think
about discrepancies in pathogenic thresholds in different parts of the cochlea.
Alternatively, modifier genes might be involved. Findings in additional families
with a mutation in the DFNA5 gene may elucidate whether other mutations in the
gene also lead to a similar type of hearing impairment or that only the putative
short protein causes hearing loss.
The  function  of  the  DFNA5  protein  is  still  unknown,  although  there  are  some
clues indicating that DFNA5, also designated ICERE-1, might be involved in the
regulation of apoptosis. Recently, Lage et al. reported that decreased DFNA5
mRNA levels are associated with a decrease in apoptotic events after exposure to
the drug etoposide.28 It appeared that increased DFNA5 mRNA  levels  are
associated with increased cellular disposition to programmed cell death mediated
by activation of caspase 3. However, it has not yet been proven that there is a
direct effect of DFNA5 on apoptosis. Interestingly, apoptosis is important in the
development  of  the  inner  ear  predominantly  during  the  embryonic  and  early
postnatal development of the cochlea.29-32 Two studies of caspase 3 knockout mice
have shown that caspase 3 deficiency results in severe hearing loss.33,34
Hyperplasia of supporting cells and degeneration of sensory hair cells and
cochlear neurons are seen in the inner ear of these mice.33,34  In 5-week-old
homozygous caspase 3 knockout mice extensive loss of hair cells was observed in
the basal and middle turns of the cochlea but not in the apical turns. Degeneration
of the hair cells begins early, progressively worsens with age and spreads from
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the basal turns towards the apical turns. These findings might explain why
DFNA5  is  a  progressive  form  of  hearing  loss  that  affects  the  higher  and  middle
frequencies earlier and more severely than the lower frequencies. The ongoing
characterization of mice in which the mutation in the original DFNA5 family is
mimicked  will  elucidate  whether  the  cochlear  defects  are  similar  to  those  in  the
caspase-3-deficient mice and thus whether DFNA5 might have a function in
apoptosis in the inner ear.35
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Abstract
Objectives: To analyse cochleovestibular impairment features in P51S COCH
mutation carriers (n=22) in a new, large Dutch family and to compare the results
to those obtained in previously identified similar mutation carriers (n=52). To
evaluate age-related features between progressive hearing and vestibular
impairment of all mutation carriers (n=74).
Study Design: Family study.
Methods: Regression analysis was performed in relation to age to outline the
development of hearing thresholds, speech recognition scores and vestibulo-
ocular reflex time constant as the key vestibular response parameter.
Results: Pure tone thresholds, phoneme recognition scores and vestibular
responses  of  the  mutation  carriers  in  the  new  family  were  essentially  similar  to
those previously established in all other mutation carriers. Hearing started to
deteriorate in all mutation carriers from 43 years of age onwards, whereas
deterioration of vestibular function started from the age of 34.
Conclusion: Vestibular impairment starts earlier, progresses more rapidly, and
eventually, is more complete than hearing impairment in P51S COCH mutation
carriers.
Introduction
The  first  DFNA9  family  with  progressive  cochleovestibular  dysfunction
developing after the age of 40, was reported by Verhagen et al.1 Eight years later,
genetic linkage was found for several American families to a locus, designated
DFNA9, on chromosome 14q12-13.2 The COCH gene was isolated from a human
foetal  cochlear  cDNA  library  and  high  levels  of  expression  were  found  in  the
cochlear and vestibular labyrinth.3 So far, five different mutations have been
identified: three American (V66G, G88E, W117R), a Dutch/Belgian (P51S) and
most recently, an Australian I109N missense mutation.4-6 Whereas hearing
impairment started in the second to third decade in the Australian and American
V66G and W117R mutations,4,6 it developed from the fifth decade onwards in the
other mutations. In 1991, glucosaminoglycan-like depositions were reported for
the first time in the cochlea of DFNA9 patients, which have been suggested to
cause the progressive cochleovestibular dysfunction.7 An alternative hypothesis is
that COCH plays a role in endolymph homeostasis.8  DFNA9 and DFNA119 are
presently the only types of non-syndromic autosomal dominant hearing
impairment with concomitant vestibular impairment.
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This report is an account of an in-depth analysis of cochleovestibular impairment
features in P51S COCH mutation carriers in a new large Dutch family, combined
with previously identified mutation carriers,1,10-17 as well as some additional newly
identified ones. Clinical results of several Dutch/Belgian P51S families have
previously been described, 7,10,13,15,18 including follow-up findings14,16,17 and  a
comprehensive cross-sectional analysis of pure tone thresholds related to age.12
These studies only included limited longitudinal observations of cochleo-
vestibular features. Recently, we identified a new large P51S COCH family  with
many carriers, of which extensive longitudinal data were available. Ophthalmo-
logic examination in this family disclosed the presence of a peculiar pattern of
corneal striae, which is the subject of a separate paper.19 Therefore, whether the
cochleovestibular findings in this family differed from those obtained in previous
studies on Dutch P51S families was checked before any data were pooled for
further analysis.
Previous cross-sectional analyses of speech recognition scores in P51S COCH
mutation carriers were limited to retrospectively collected incidental
measurements in patients from several different families.11 In the present family, it
was possible to perform speech audiometry prospectively in all mutation carriers
with hearing impairment symptoms.
Vestibular examination was also performed in most of these affected family
members, which allowed for an intrafamilial quantitative cross-sectional analysis
of vestibular response parameters in relation to age. This analysis could be
extended to a suprafamilial one by adding vestibular test results obtained in all
our other P51S COCH mutation carriers. Finally, it was possible to compare
between estimates of onset age and rate of hearing deterioration as well as
vestibular dysfunction from all simultaneously collected cross-sectional vestibular
and hearing impairment data.
Patients and Methods
Forty-four family members of a new Dutch family harbouring the P51S COCH
trait participated in this study. Signed informed consent was obtained from all
participants. Medical history was taken, with special attention paid to vestibular,
ocular and hearing impairment symptoms. Non-hereditary causes of hearing
impairment were excluded. All individuals underwent otoscopic examination and
pure tone audiometry. Speech audiometry and vestibular function tests were
performed  in  clinically  affected  persons.  Guided  by  the  clinical  findings, COCH
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mutation analysis was performed in all of them, which confirmed the presence of
the disease-causing P51S mutation.
Four affected family members underwent brainstem auditory evoked potential
(BAEP) examination. One person previously underwent computerized tomo-
graphy and in four persons magnetic resonance imaging of the temporal bones
was performed.
Audiometry and data analysis
Pure tone and speech audiometry were  performed in  a  sound treated room,  the
former according to the norms of the International Standard Organization
(ISO).20,21 Threshold was fixed at an arbitrary value of 130 dB hearing level for out-
of-scale measurements. The individual 95th percentile  threshold  values  of
presbyacusis (P95) in relation to sex and age were derived for each frequency,
using the ISO 7029 method.22 Subjects were considered affected if the best hearing
ear showed thresholds beyond the P95. Longitudinal regression analysis was
performed of binaural mean threshold values on age in clinically affected persons
with three or more consecutive measurements at ages of less than 70 years and a
follow-up interval of more than three years. The regression coefficient (slope) was
called annual threshold deterioration (ATD), expressed in dB per year.
Progression was significant if the 95% confidence interval of the ATD did not
include zero. An analysis similar to analysis of covariance (ANCOVA, Prism PC
version 3; GraphPad, San Diego CA, U.S.A.) was performed to compare between
slopes and intercepts of the regression lines, pertaining to individual
measurements per frequency. As pooled regression appeared to be inappropriate,
the median slope (ATD) and Y intercept were calculated to establish a trend line
for each frequency. Because the trend line thus obtained only reflected the
longitudinally analysed cases, we checked whether the total numbers of affected
persons (i.e. including those who did not undergo longitudinal analysis) covered
by data points above and below the trend line were about equal for each separate
frequency. The results obtained in the present longitudinal data analysis were
compared with the results of a cross-sectional analysis (last-visit thresholds) for 52
other Dutch P51S COCH mutation carriers (see Table 3 for equation).12 Those
carriers were selected who had simultaneous measurements of pure tone hearing
thresholds and vestibulo-ocular reflex (VOR) parameters. In addition,
longitudinal measurements (follow-up interval 2-12 years) were available in 10 of
these carriers.
Speech audiometry was performed using a standard monosyllabic (consonant-
vocal-consonant) Dutch word list. Maximum monaural phoneme scores
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(percentage correct recognition) were derived from individual performance
versus intensity plots. Cross-sectional recognition scores averaged for both ears
were plotted against age and binaural mean pure tone average (PTA1,2,4 kHz) in dB
hearing level. In the performance versus impairment plot, nonlinear regression
analysis was used to fit sigmoidal dose-response curves with a variable slope
(same equation as included in Table 3). The age of onset and the onset level (i.e.
X90) were defined at a recognition score of 90% in a performance (Y) versus age or
versus impairment (X) plot, respectively. For X90 > X > X30,  a  straight  line  was
fitted to simplify the results and to obtain an estimate of local average slope that
was called deterioration rate in the score-against-age plot and deterioration
gradient in the score-against-PTA1,2,4 kHz plot.11 The  results  of  the  present  single-
family cross-sectional data analysis were compared with the results of a
previously performed multi-family analysis in P51S COCH mutation carriers.11
Vestibular examination and data analysis
Twenty-two of the affected persons underwent vestibular examination with eyes
open in the dark, employing a rotatory chair to perform a 90°/s velocity step test
in two directions with electronystagmography and computer analysis, as
previously described.23 The time constant T (s) was elected to characterize the
VOR. As this parameter shows a lognormal distribution,24 the geometric mean for
both nystagmus directions was used for further analysis. The 90% (P5-P95)
confidence interval for this parameter was 13-23 s. Table 1 shows the classification
by T value used to categorize the VOR findings obtained with the velocity step
test.
Table 1. Classification of VOR findings in velocity-step test according to the value of the
time constant (T).
Hyporeflexia with an ultrashort time constant (T < 5 s) was labelled as a separate
category of severe hyporeflexia, that is close to areflexia, because primate afferent
vestibular neuron recordings have shown that time constants generally are not
below five seconds.25 In addition, nystagmic rotatory responses exhibiting shorter
T (s) Classification
> 23 Hyperreflexia
13-23 Normal
5-12 Hyporeflexia
< 5 Severe hyporeflexia, close to areflexia
0 Areflexia
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time constants have been suggested to be of extravestibular, presumably
somatosensory, origin.15,26 An  arbitrary  zero  (T  =  0)  was  assigned  to  rotatory
responses showing no or just a few nystagmus beats. For the sake of comparison,
as well as for potential extension of the present data, we retrieved similar last-visit
data from the 52 additional mutation carriers specified above. Nonlinear cross-
sectional regression analysis of T on age was performed for this combined group
and the present group of mutation carriers, separately. Student’s t test was used to
compare between the fitted parameter values in both groups, including Welch’s
correction if Bartlett’s test identified unequal variances. The level of significance
used in all tests was p= 0.05.
Figure 1. Part of the pedigree of a new Dutch family with the P51S COCH trait. Only
affected participants are included, together with deceased affected family members.
Filled symbols indicate mutation carriers, open symbols non-carriers. Squares represent
men, circles women. Please note that generation lines of different lengths have been used
to compact the figure; generation is included in symbol legend.
Results
General findings and hearing impairment symptoms
The pedigree of the new family (Figure 1; modified for reasons of privacy)
comprised 44 affected family members, 30 of whom were alive and participated in
this study. By history, person II:7 did not have profound cochleovestibular
impairment when he died at 54 years of age. Otoscopic examination was normal,
except in one case (IV:25), in which a granulomatous thickened eardrum
(myringitis granulomatosa) was noted. One patient (III:8) had received a cochlear
I:2I:1
II:2 II:5 II:7II:3 II:10II:1
III:1 III:5III:3III:2
IV:1 IV:4 IV:6IV:3 IV:7IV:5
V:3 V:4
III:4
IV:8 IV:10
II:6
III:13 III:14 III:16III:12
IV:17 IV:18IV:16
V:6
III:15
IV:19 IV:21
II:8
III:17 III:18
IV:24 IV:25IV:23
II:9
III:20III:19
II:4
III:6 III:8 III:10III:7
IV:11
III:9
IV:13IV:12
III:11
IV:14 IV:15
IV:2
V:2V:1
IV:20
V:7
IV:22
V:8
IV:9
V:5
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implant at age 70 and only the pre-implant data were used for the present
analysis. The mean onset of self-reported hearing impairment symptoms was 39
years (range: 18-51 years). Pure tone audiometry indicated that 20 family
members were affected. Asymmetry and variability in progression were also
noted  in  this  family  and  were  fairly  similar  to  previous  findings  in  other  P51S
families.11,17,27 Tinnitus  was  mentioned  by  nine  of  the  present  mutation  carriers
(Table 2).
Table 2. VOR findings in 22 examined mutation carriers of the present family shown
together with age, binaural mean hearing level and presence or absence of tinnitus
Person
nr.
Age
(years)
Vestibular function:
VOR
PTA1,2,4 kHz
(dB HL)
Tinnitus
V:3 24 Hyperreflexia 2 No
V:7 25 Normal 13 No
V:1 31 Normal 2 No
IV:11 41 Severe hyporeflexia 51 Yes
IV:25 41 Severe hyporeflexia 26 No
IV:13 42 Severe hyporeflexia 4 No
V:5 43 Normal 2 No
IV:24 44 Severe hyporeflexia 46 No
IV:23 48 Hyporeflexia 34 No
IV:7 50 Areflexia 38 Yes
IV:18 50 Hyporeflexia 32 Yes
IV:3 53 Areflexia 52 Yes
IV:6 54 Severe hyporeflexia 54 Yes
IV:17 54 Areflexia 64 No
IV:4 56 Areflexia 38 Yes
IV:1 57 Areflexia 48 Yes
IV:19 60 Areflexia 69 No
IV:10 61 Areflexia 64 Yes
III:10 61 Areflexia 83 No
III:8 69 Areflexia 128 No
IV:8 69 Areflexia 85 No
III:17 77 Areflexia 97 Yes
Figure 2 compares the binaural mean PTA1,2,4 kHz levels between mutation carriers
with and without tinnitus, controlling for the patient’s age. The two regression
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lines were not significantly different, which implies that the presence of tinnitus
did not clearly depend on the extent of hearing impairment.
Figure 2. Comparison of binaural mean PTA1,2,4 kHz (dB hearing level) between the present
mutation carriers with (filled circles, solid regression line) and without (open circles,
dashed regression line) tinnitus, controlling for age (years). The regression lines do not
differ significantly (see Methods). HL, hearing level.
BAEP examination showed pathological delay with amplitude attenuation of
wave V on the left side in one person (IV:1). BAEPs were normal in three other
affected persons (IV:8, IV:12 and IV:24). Additional computerized tomography
scans (III:8) and magnetic resonance imaging analyses (IV:1, IV:3, IV:17 and IV:24)
were unremarkable.
Audiologic and vestibular features related to age
Figure 3 covers all individual threshold measurements obtained from affected
members of the present family. The ATD (dotted trend line) ranged from 1.9 dB
per year (0.5 kHz) to 3.3 dB per year (8 kHz). Extrapolation of the trend line to
threshold zero suggested an onset age for progression in the range of 27 to 42
years;  however,  the  validity  of  such  an  extrapolation  can  be  doubted.  The
sigmoidal curves, fitted to the cross-sectional threshold data of the previously
identified mutation carriers (see Methods; data points not shown in Figure 3),
matched fairly well with the threshold data of the present mutation carriers. We
therefore concluded that pooling of cross-sectional hearing threshold data of all
mutation carriers was appropriate (see below).
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Figure 3. Longitudinal analyses of hearing impairment (binaural mean air conduction
threshold) for the present mutation carriers. Threshold data (in dB hearing level) versus
age (in years) for all frequencies combining individual longitudinal data (open circles
with connecting hairlines and fitted regression line) and other measurements (open
circles without regression lines, or filled circles) of 20 mutation carriers. Bold regression
lines indicate significant progression. In each panel, the dotted straight line is the trend
line (see Methods). The slope of this line is indicated in bold. The dashed sigmoidal curve
in bold was fitted to the cross-sectional threshold-on-age data (data points themselves not
shown) of all mutation carriers except those of the present family. HL, hearing level.
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Figure 4. Cross-sectional binaural mean phoneme recognition scores at last visit against
age (A) and binaural mean PTA 1, 2, 4 kHz (B) in the present mutation carriers. The dotted
lines with bold number indicate onset age and onset level. The dashed line in part B
indicates “local average” slope for X90 > X > X30. Bold numbers near the regression line
indicate deterioration rate (A) and deterioration gradient (B). HL, hearing level.
The speech recognition scores of the present mutation carriers gradually declined
to about 50% at an age of 66 years (Figure 4A). Onset age X90 was 49 years, from
which the recognition score deteriorated by 2.3% per year on average. The 90%
recognition score was found at a PTA1,2,4 kHz level of 46 dB (Figure 4B) and
deteriorated by 1.2% per dB on average for X90 > X > X30. These values compared
fairly well to those previously obtained in P51S mutation carriers from several
different families11 (original data and fitted parameter values not shown).
Vestibular examination was performed on 22 mutation carriers of the present
family, preferably those having cochleovestibular symptoms, aged 24 to 77 years
(Table 2). Eighteen persons had experienced characteristic vestibular
symptoms.15,17 Eleven persons had experienced attacks of vertigo lasting up to half
a  day,  most  often  not  accompanied  by  nausea.  Three  persons  had  paroxysmal
vertigo similar to Ménière’s disease, with hearing impairment and symptoms of
threshold fluctuations. Aural fullness was absent.
In Table 2 the classified results of the vestibular examination are shown sorted by
age. Vestibular areflexia was found in 11 of the 13 persons aged 50 years and
older. Severe hyporeflexia was found in four of the nine younger individuals at
ages 41 to 44 years. Person IV:13 showed severe hyporeflexia with still normal
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audiometry. He recently experienced his first attack of vertigo. Person V:5 was the
only one older than 40 years who had not yet developed any vestibular or hearing
impairment symptoms. Unfortunately there were no affected family members
examined between the ages of 31 and 41; however, five persons clearly
remembered the distinct appearance of vestibular symptoms prior to hearing
impairment symptoms.
Figure 5. Mean VOR time constant (symbol x, solid sigmoidal curve in bold, T in s, left Y
axis) plotted against age (years) for all available (n = 74) P51S COCH mutation carriers
including the present mutation carriers (n = 22). An arbitrary zero represents vestibular
areflexia. The 5th and 95th normal percentile values are shown as dashed horizontal
hairlines. For comparison, simultaneously measured PTA0.25-2 kHz values (dB hearing level)
data of all mutation carriers (open circles, dashed curve in bold, right axis) are included.
See Table 3 for parameter values of sigmoidal curves.
Figure 5 shows the value of the response parameter T plotted against age for all
carriers of the P51S mutation (n = 74), including the carriers of the present family
(n = 22). In case of vestibular areflexia, arbitrary zeros were plotted. Because no
significant difference was found of any fitted regression parameter value (data not
shown) in the present mutation carriers (n = 22) compared with those of the other
carriers (n = 52), pooling of data was performed. T decreased from a top level of 21
seconds to virtually zero. In the initial stage of vestibular dysfunction, some of the
carriers showed long time constants (T > 23 s), characteristic of vestibular hyper-
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reactivity. The plot demonstrates that hyporeflexia (T < 13 s) is likely to appear by
the end of the fourth decade of life and severe hyporeflexia (T < 5 s) somewhere in
the fifth decade.
Table 3. Results of nonlinear regression analysis (sigmoidal model, equation below) of Y,
i.e. threshold (binaural mean PTA0.25-2 kHz) or VOR time constant T, on X,  i.e.  age  in  the
P51S mutation carriers.
Parameter
Y PTA
(dB HL)
T
(s)
Comment
N 74 74
Bottom 10 ± 5 a 0 constant Offset level
(0% of deterioration trajectory)
Top 99 ± 11 21 ± 2 Saturation (completion) level
(100% of deterioration trajectory)
H* 7.7 ± 2.1 -12 ± 3 Hill slope, slope factor
or Hill coefficient
X10* 43(38-49)b 49(45-53) Onset age (hearing) and
completion age (vestibular) of impairment
X50* 57(53-62) 41(38-43) Age at 50% of
deterioration trajectory
X90* 76 (61-95) 34(29-39) Onset age (vestibular) and
completion age (hearing) of impairment
Equation
Y = Bottom + (Top-Bottom)/(1+10(logX50-logX)H)
X, age (years); Y, T (s) or PTA0.25-2 kHz (dB HL)
*, applies to logarithmic age scale (not shown);
a, ± 1 SE (standard error); b, 95% confidence interval (SE defined only for logarithmic scale), HL,
hearing level.
Onset age of obvious deterioration of the VOR (X90) was estimated at 34 years of
age (Table 3). From that age onwards, T showed a maximum decrease of 1.5
seconds per year (Figure 5). Onset of vestibular impairment seems to occur earlier
than onset of obvious progression in hearing impairment. We therefore tested for
the pooled, simultaneously collected hearing threshold and vestibular response
data in the P51S mutation carriers (n = 74) whether the difference in onset age was
significant in a formal way, that is, pertaining to logX90 (vestibular, regression of T
on log age) and logX10 (hearing loss, regression of PTA0.25-2 kHz on log age). We
chose the PTA0.25-2 kHz to  represent  the  threshold  findings,  first  because  the
sigmoidal regression curves were fairly similar within the frequency range of 0.25
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to 2 kHz and second because there was reason to believe that regression at 4 to 8
kHz was biased.12 Student’s t test indeed revealed a significant difference. Similar
findings were obtained when testing the ages at which 50% or 90% completion of
progression (vestibular versus hearing impairment) had been accomplished
(Table 3). Notably, the difference between the 90% completion ages (49 and 76
years, respectively) was far greater (27 years) than the difference between the
onset ages (9 years). Such a finding suggests higher progression of vestibular
impairment than of hearing impairment, although the difference in Hill slope
between the curves was not significant (see below). It was also remarkable that
the VOR was lost, whereas residual hearing persisted (Table 3, top level, i.e. 100%
completion of progression trajectory for PTA0.25-2 kHz, was 99 dB hearing level).
Figure 6. Normalizing transformations (0-100% completion scale) for T (Tnorm,  symbol  x
and solid line) and PTA0.25-2 kHz (PTAnorm, open circles and dashed line) plotted against age
(A) and linear regression lines (bold, solid for T, dashed for PTA) fitted for X10 < X < X90
(B). Thin curves in part B are the same as bold ones in part A. Note that 0% completion of
impairment corresponds to T = 21 s and PTA0.25-2 kHz = 10 dB hearing level, respectively
(see Table 3); 100% completion of impairment corresponds to T = 0 and PTA0.25-2 kHz = 99
dB hearing level, respectively, and the curve spans 21 s for T and 89 dB hearing level for
PTA0.25-2 kHz.
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To facilitate a comparison between the trajectories outlining the deterioration of
vestibular function and hearing, the data were normalized (Figure 6). The
sigmoidal curves were now fitted with constant values for top (100% completion)
and  bottom  (0%  completion),  which  might  improve  the  fit  of  Hill  slope.  The
values of Hill slope still did not differ significantly between the curves (Figure
6A). We therefore focused the analysis on slope and fitted the linear regression
line close to the inflection point of the sigmoidal curve for X10 < X < X90 to obtain an
estimate of local average slope, similar to the analyses of phoneme scores
(Methods). The slope, now equivalent to a deterioration rate, was 6.9% per year
for normalized T and 2.9% per year for normalized PTA0.25-2 kHz, respectively
(Figure 6B). ANCOVA indicated that the slopes were significantly different.
Discussion
In this report, a new, large family is described with the frequently observed P51S
mutation in the COCH gene and cochleovestibular features similar to those
previously  outlined  in  other  P51S  mutation  carriers.  Sensorineural  hearing
impairment was predominant in the high frequencies and started at the lower
frequencies, presumably from about 40 years onwards. Asymmetric thresholds
and variable progression occur often in P51S COCH families.10,17,27 The present
family showed similar types of audiograms and ATD, as has been previously
described in other P51S COCH families.10,12,17 Therefore, the picture emerging from
the present cross-sectional analysis of the pooled threshold-on-age data can be
regarded as representative for all P51S COCH mutation carriers.
The results of the analysis of speech recognition scores in the present family, were
comparable to those previously reported for P51S carriers from several different
families.11 Specific retrocochlear pathology could not be traced.
The present cross-sectional data of vestibular impairment were similar to those
previously reported for several different P51S COCH families. 1, 10,13,15-17 For this
reason, the present analysis can also be taken as representative for all P51S
mutation carriers. Initially, Ménière-like symptoms may be prominent8,14,16,18,27 and
vestibular hyperreactivity may be found.16 Later on, loss of vestibular function
develops, eventually leading to vestibular areflexia. Complete failure of function
develops not only in the semicircular canal system but also in the otolith system.15
Head-movement-dependent oscillopsia therefore develops in all of these mutation
carriers and underwater orientation becomes impossible. Enhancement of the
cervico-ocular reflex attests to the absence of VOR activity.28 This enhanced reflex,
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as well as enhanced optokinetic nystagmus responses,29 compensate for at least
part of the deficit of the afferent vestibular system.
The present quantitative data analysis outlines the development of progressive
vestibular failure developing from the fourth decade into the sixth decade of life.
It appeared that vestibular impairment developed by about 9 years earlier and
deteriorated more rapid (4% per year) than hearing impairment. Deterioration of
vestibular function had almost completed when hearing deterioration had only
just begun to develop (Figures 5 and 6, Table 3). In addition, residual hearing
persisted into old age.
Concluding remarks
The analyses performed in the present family provided convincing evidence that
all key features were comparable across all Dutch P51S COCH mutation carriers
examined, including the present ones. The development of vestibular failure
could now be analysed in a formal, quantitative way, not only for the present
subjects but also for the whole ensemble of mutation carriers. A similar analysis of
the development of hearing impairment with advancing age, based on
simultaneous  original  measurements  in  the  same  mutation  carriers,  some  still
being asymptomatic, allowed for statistical testing between the respective onset
ages and slopes. It showed that vestibular deterioration starts earlier, progresses
more rapidly and, eventually, is more complete than hearing deterioration in P51S
COCH mutation carriers.
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Abstract
Purpose: Investigation of a possible association between vertical corneal striae and
mutations in the COCH gene,  observed  in  four  DFNA9  families  with  autosomal
dominant hearing loss and vestibular dysfunction.
Design: Prospective case-series.
Methods: Ophthalmologic examinations with photography of the cornea after
instillation of fluorescein were performed in 98 family members with 61 mutation
carriers of four DFNA9 families at the Radboud University Nijmegen Medical
Centre. Families 1 and 2 harbour the Pro51Ser mutation, and families 3 and 4
harbour the Gly88Glu and the Gly87Trp mutation, respectively. Statistical
analysis was performed to find an association between the vertical corneal striae
and the COCH mutation for each family and to test whether the four families were
different in this respect.
Results: The vertical corneal striae were exclusively visible after instillation of
fluorescein.  They  caused  minor  problems,  as  dry  eye  symptoms,  and  were  not
present in the general Dutch ophthalmologic population. The striae were present
from an age of 47 years in 32 individuals, of whom 27 individuals had a COCH
mutation. Statistical analysis on the striae and the COCH mutations showed a
significant association in families 1, 2 and 3 (p=0.0006), but not in family 4
(p=0.63).
Conclusions:  Data analysis demonstrated a significant association between
vertical corneal striae and the Pro51Ser and Gly88Glu mutations in the COCH
gene in DFNA9 families 1, 2 and 3 with cochleovestibular dysfunction. Our
findings suggest that the vertical corneal striae and cochleovestibular dysfunction
may be caused by the same COCH mutations.
Introduction
Non-syndromic autosomal dominantly inherited forms of hearing loss are
designated as “DFNA”, followed by the number of identification in chronological
sequence. DFNA9/COCH causes mid-life onset of progressive hearing loss,
predominantly in the high frequencies, with mid-life onset of progressive
vestibular dysfunction.1-15 At present, nine different exonic and non-synonymous
mutations have been identified in the COCH gene: Val66Gly,16 Gly88Glu,16
Trp117Arg,16 Pro51Ser,7,17 Ile109Asn,10 Ala119Thr,18 Val104del,19 Cys542Phe20 and
Gly87Trp.21 All mutations affect the LCCL domain of the protein,22 except for the
mutation causing the Cys542Phe substitution, which is located at the vWFA2
domain.20 The function of cochlin is still unclear. COCH encodes the extracellular
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matrix protein cochlin, which is expressed in the cochlear fibrocytes of the spiral
ligament, spiral limbus and osseous spiral lamina and in the fibrocytes of the
stroma underlying the sensory epithelium of the crista ampullaris of the semi-
circular canals.23,24
We discovered a peculiar pattern of mid-life onset vertical corneal striae in three
families with a mutation in the COCH gene,  which  is  not  found  in  the  general
Dutch ophthalmologic population. This is the first report on structural
abnormalities in the anterior part of the eye in DFNA9/COCH. Ocular
abnormalities in non-syndromic autosomal dominant sensorineural hearing loss
have only been reported earlier in DFNA11/MYO7A with subclinical retinal
involvement.25
Methods
Ninety-eight  family  members  of  four  Dutch DFNA9/COCH families participated
in this study at the Radboud University Nijmegen Medical Centre. Families 1 and
2 carried the Pro51Ser mutation,8,15 family 3 carried the Gly88Glu mutation,13 and
the Gly87Trp mutation was present in family 4.21 The mutations were identified by
restriction digestion in the first two families 8,15 and by sequencing the gene in the
third and fourth family.13,21 The  study  was  approved  by  the  local  medical  ethics
committee. Signed informed consent was obtained from all participants. Medical
history was recorded with special attention to ocular symptoms. Ophthalmologic
history data were retrieved. Haplotype analysis proved that families 1 and 2 have
the same common founder as has been previously shown for the majority of the
investigated families with the Pro51Ser mutation.26
Slit-lamp examination was performed with and without fluorescein paper strips,
using the slit-lamp microscope with a broad beam and a cobalt blue filter. Corneas
were photographed by tangential illumination of the limbus with white light and
after application of fluorescein. After fluorescein installation in the lower fornix,
the  patient  was  asked  to  blink  several  times.  Rubbing  the  eyes  was  strictly
avoided. The corneal surface curvature was measured by Javal keratometry and
the corneal thickness was tested by ultrasound pachymetry. Best corrected visual
acuity was documented. Intraocular pressure was determined by Goldmann
applanation tonometry. The Schirmer test was used to evaluate tear production.
To screen for possible age-dependent differences, intraocular pressure, kerato-
metry, Schirmer test, and visual acuity data were plotted against age. Both
mutation carriers with the vertical striae and carriers who did not exhibit these
striae were compared.
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Figure 1. Pedigrees of DFNA9 families 1 to 4 with vertical corneal striae. A cross above
the symbol indicates that ophthalmologic examination has been performed. Grey right
half of the symbol = vertical corneal striae; black left half of the symbol = COCH mutation;
open right half symbol = no vertical corneal striae; open left half symbol = no COCH
mutation; square = man; circle = woman; Slashed symbol = deceased person; completely
black symbol = clinically affected individual, not genetically tested; arrow = proband. The
individuals have the same identification number as in the original pedigrees. The
pedigrees have been simplified. The youngest generation is not shown for privacy
reasons. Please note that generation lines of different lengths have been used in order to
compact the figure.
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Fisher’s exact test and chi-square test were performed on separate and grouped
family data to detect a possible association between the occurrences of the vertical
corneal striae and the COCH mutation.
Results
In the pedigrees of the four DFNA9/COCH families  shown  in  Figure  1,  the
presence of both the vertical corneal striae and the COCH mutation are indicated.
The first number of the identification code is the number of the family. The second
number (after the dot) represents the identification code of the patient in the
original pedigree. The mean age of the participants was 50.6 years. Sixty-one
individuals were mutation carriers. Vertical corneal striae were present in 32
individuals, of whom 27 had a COCH mutation. Surprisingly, the striae were also
found in corneas of four members of family 1 without a COCH mutation (1.IV29-
31, 1.III21) and in one member of family 3 without a COCH mutation (3.III30). In
family 1, three were siblings and one of them only showed vertical corneal striae
exclusively on the right cornea. In family 4,  only one of the 19 mutation carriers
(4.III71) had vertical corneal striae in the right eye. This person had keratoconus of
both eyes and the left cornea had been transplanted.
Most of the affected persons had dry eye symptoms and showed conjunctival
hyperaemia and instability of refraction and vision. Foreign body sensation and
photophobia were also prominent symptoms. Several persons experienced
problematic adjustment to glasses because of refraction instability. The proband of
family 1 (1.IV6) had the most severe symptoms. Because of severely dry eyes, she
had  permanent  lacrimal  punctal  plugs  inserted  bilaterally.  She  and  her  sister
(1.IV4)  complained  about  such  fluctuations  in  vision  for  years  to  the  extent  that
spectacles no longer helped. They had used bandage lenses for years. Only two
persons (1.V3, 1.V13) used hard contact lenses, of which individual 1.V3 showed
the vertical corneal striae.
Slit-lamp examination with fluorescein revealed spontaneously visible (i.e. not
elicited by rubbing) vertical corneal striae highlighted in the superficial layers of
the central cornea (Figure 2). However, in one person without a COCH mutation
(3.III30), the striae were only visible in the upper half of both corneas. Illuminated
striae were visible against a dark blue background. The vertical corneal striae
were best visible after cessation of blinking for about ten seconds and gradually
vanished after a few minutes. The vertical corneal striae had a mid-life onset, as
they  were  visible  from  an  age  of  about  47  years  onwards.  In  the  younger
generation, only the two siblings of the proband (1.V3, 4; age 25, 23 years) showed
very faint striae. The pattern of the striae appeared to be reproducible: photo-
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graphs taken one hour to several months later still showed the same pattern of
striae (Figure 2). As a rule, rubbing was avoided, but, apart from that, rubbing
was done deliberately in some cases to see if this changed the pattern. The vertical
corneal striae became more pronounced by rubbing, but the pattern itself did not
change.  Efforts  to  expose  the  vertical  corneal  striae  by tangential  illumination of
the  limbus  with  white  light  were  unsuccessful.  Ultrasound  pachymetry  of  the
central cornea of eight eyes (four patients) with vertical corneal striae were within
normal limits (mean, 519 µm; range 507-554 µm). Other results of ophthalmologic
examinations are shown in the appendix table.
      A B
Figure 2. Vertical corneal striae in one person with DFNA9. Corneal photographs of case
1.IV6 (2A), and of case 1.IV6 taken two weeks later (2B), showing the typical vertical
corneal striae to be reproducible.
The results of intraocular pressure measurements, Schirmer test, Javal
keratometry, and visual acuity test of the mutation carriers with versus without
the vertical corneal striae were compared (Figure 3), to find out whether there
were age-dependent differences. The mutation carriers with the vertical corneal
striae tended to show higher intraocular pressure and a lower corneal radius.
However, no significant difference in either of these parameters could be detected
between mutation carriers with or without striae (Figure 3A and 3C). Intraocular
pressures were within the normal range. Most of the mutation carriers with the
striae had reduced tear production with the Schirmer test (Figure 3B), in line with
their symptoms and clinical examination. There was no significant difference
detected in visual acuity.
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Figure 3. Ocular testing of DFNA9 family members with and without the vertical corneal
striae. Comparison of the ocular test results between mutation carriers with the vertical
corneal striae (filled circles) and mutation carriers without the striae (open circles) plotted
against age. Figure 3A. Results of intraocular pressure in mmHg. Figure 3B. Results of
Schirmer lacrimation test in mm per 5 min. Figure 3C. Results of Javal keratometry
readings in mm. Figure 3D. Results of visual acuity test.
The percentage prevalence of vertical corneal striae in mutation carriers in
families 1 to 4 (age > 47 years) was 93, 78, 57, and 10 (%) respectively (ntotal, fam1-
4=40). With Fisher’s exact test a significant association was found between the
presence of the COCH mutation and the vertical corneal striae in families 1, 2, and
3 (p=0.0006), but not in family 4 (p=0.63). There was no significant difference in
prevalence detected among the first three families (p=0.37).
Discussion
The spontaneously visible vertical corneal striae were present in 32 individuals of
four DFNA9/COCH families, of whom 27 were mutation carriers. A significant
association between the cochleovestibular and corneal features was found in
families 1, 2, and 3, but not in family 4. Because families 1, 2, and 3 harbour two
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different COCH mutations (Pro51Ser and Gly88Glu) and the vertical corneal striae
are not found in the normal Dutch ophthalmologic population, the association of
the COCH mutations and the corneal vertical striae suggests that mutations in the
COCH gene can cause both the cochleovestibular and the corneal features. This is
corroborated by the fact that transcripts of the COCH gene can be detected in the
cornea by RT-PCR (Kremer, unpublished data). There is as yet no clear
explanation why the corneal phenotype was not present in family 4 (Gly87Trp),
and why the vertical corneal striae also were present in five individuals without a
proven COCH mutation.
The possibility of two different neighbour genes causing cosegregation of two
phenotypes could still not be ruled out. Recombination events could explain why
four persons in family 1 and one person in family 2 with vertical corneal striae did
not have the mutation in the COCH gene and why not all COCH mutation carriers
exhibit the striae. On the contrary, the latter can be caused by reduced penetrance.
Nevertheless,  this  two-gene  theory  is  not  likely,  because  the  striae  are  not
described previously and are visible in individuals with two different mutations
in the COCH gene.
Further support of a COCH gene mutation as a cause of the vertical corneal striae
is the identification of co-deposits of cochlin and acidophilic mucopolysaccharide
in  the  trabecular  meshwork  around  Schlemm’s  canal  of  patients  with  primary
open angle glaucoma, and in glaucomatous DBA/2J mice with progressive
hearing loss.27,28 Similar abnormal acidophilic mucopolysaccharide deposits have
been  described  in  the  inner  ear  of  DFNA9  patients.24,30-32 Electron microscopic
examination of the cochlea showed that the deposits consist of highly branched
microfibrils that interfere with normal fibrillogenesis, causing degradation of
collagen type II.33 This  decrease  in  collagen  type  II  was  also  found  in  the
trabecular meshwork from an age of 40 to 45 years onwards. Remarkably, the
cochleovestibular dysfunction becomes prominent from this age in DFNA9
patients, as well as the vertical corneal striae.
The  cochleovestibular  phenotype  is  similar  in  all  four  DFNA9/COCH families.
Hearing  impairment  starts  in  the  fifth  decade  with  progression  to  profound
hearing loss. Vestibular dysfunction begins, prior to the hearing impairment, at 35
years of age and leads to complete vestibular areflexia in families with the
Pro51Ser mutation (families 1 and 2). The onset age seems to be higher in the
families with the Gly88Glu and the Gly87Trp mutation (family 3 and 4).
Vestibular dysfunction is fully penetrant in families with the Pro51ser mutation,
and is less in the families with the Gly87Trp substitution and the Gly88Glu
mutation.8,13,15,29
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The  vertical  corneal  striae  in  the  present  study  were  different  from  the  anterior
corneal mosaic, described by Bron.34-38 Whereas the vertical corneal striae in the
DFNA9 patients were visible without any manipulation or abnormal intraocular
pressure, the anterior corneal mosaic was only detectable in hypotonic eyes or in
normal eyes after applying external pressure.35,39 Also, the vertical corneal striae in
the present corneas had an exclusively vertical direction, but the pattern of the
anterior corneal mosaic was honeycomb-like, elongated obliquely, vertically or
horizontally.36
Comparison of the ophthalmologic examinations in the mutation carriers with
and without the vertical corneal striae is important to investigate the pathogenesis
of the vertical corneal striae. From the age of 47 years onwards, intraocular
pressures  in  the  mutation  carriers  with  the  vertical  corneal  striae  were  within
normal limits, but tended to be higher than in the carriers without the striae. The
results of the Schirmer test showed subnormal values in the older age group with
the vertical corneal striae, supporting the association of the striae with dry eye
syndrome.
These findings indicate that ophthalmologic examination of DFNA9/COCH
families, especially those having a mutation different from the Pro51Ser mutation,
may be worthwhile to strengthen or weaken the suggestion that COCH mutations
cause both the cochleovestibular and corneal features. Additional studies at the
molecular level of the inner ear and cornea are necessary to elucidate the
pathogenic mechanism.
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APPENDIX
Results of COCH Mutation Analysis, Corneal Findings and Ophthalmologic Examination
in Four DFNA9 Families
Family 1
Patient
Code
Gender
Age (y)
Mutation Visual
acuity
Cornea Keratometry
(mm)
Schirmer
(mm 5
min)
IOP
(mm Hg)
Other findings
RE     LE RE       LE RE     LE RE    LE
1 1.V9 F, 18 - 0.9     0.9 Normal 7,42     7,42 Congenital cataract
2 1.V12 M, 19 - 1.0     1.0 Normal 7,51     7,43
3 1.V4 F, 23 + 1.0     1.0 Corneal striae Dry eyes
4 1.V3 M, 25 + 1.0     1.0 Corneal striae Dry eyes, hard contact
lenses
5 1.V7 M, 26 + 1.0     1.0 Normal 7,61     7,62
6 1.V6 F, 27 + 1.0     1.0 Normal
7 1.V13 F, 29 - 1.0     1.0 Normal 7,88     7,89 Hard contact lenses
8 1.V8 M, 30 + 1.0     1.0 Normal
9 1.V1 F, 31 + 1.0     1.0 Normal 7,49     7,55 Refraction instability
10 1.V711 F, 38 - 1.0     1.0 Normal
11 1.V10 M, 40 - 1.0     1.0 Normal 7,95     7,93
12 1.V25 M, 42 + 1.0     1.2 Normal 8,28     8,30 13     15
13 1.V5 F, 43 + 1.0     1.0 Normal
14 1.IV24 M, 45 + 1.0     1.0 Normal
15 1.IV12 F, 47 + 1.0     1.0 Normal 8,00     7,92 22     19 16     16
16 1.IV3 M, 48 + 1.0     1.0 Corneal striae
17 1.IV28 M, 48 - 1.0     1.0 Normal
18 1.IV31 M, 49 - 1.0     0.8 Corneal striae Dry eyes
19 1.IV7 F, 50 + 1.0     0.8 Corneal striae 7,48     7,81 Incipient cataract
20 1.IV18 F, 50 + Corneal striae
21 1.IV32 F, 52 - 1.0     1.0 Normal 7,70     7,76 21     25 Cornea guttata
22 1.IV30 M, 53 - Corneal striae
23 1.IV29 M, 54 - 1.0     0.8 Corneal striae 14     13 Dry eyes
24 1.IV21 M, 54 + 1.0     1.0 Corneal striae 7,63     7,83 irr
25 1.IV6 F, 54 + 0.8     0.9 Corneal striae 7,46     7,31 0       2 15     16 Dry eyes, refraction
instability
26 1.IV17 F, 55 + 1.0     0.8 Corneal striae 14     13 Dry eyes, refraction
instability
27 1.IV4 F, 56 + 1.0     1.0 Corneal striae 7,39     7,36 irr 8       7 Refraction instability
28 1.IV1 M, 57 + 0.8     0.8 Corneal striae 7,28     7,43 10     11 Refraction instability,
corneal Stahli line
29 1.IV19 M, 60 + Corneal striae Cornea guttata,
cataract surgery
30 1.IV10 F, 61 + Corneal striae 9       6 Strabismus surgery
31 1.IV8 M, 70 + Corneal striae 5       6 18     16
32 1.III8 M, 72 + 0.6      0.8 Corneal striae 2       5 18     18
33 1.III21 F, 76 - 1.3      0.1 Corneal striae Venous occlusion LE
34 1.III17 F, 77 + 0.8      0.8 Corneal striae 25     25 18     18 Dry eyes
IOP = intraocular pressure; RE = right eye; LE = left eye; irr = irregular; Visual acuity = best corrected visual
acuity.
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Family 2
Patient
Code
Gender
Age (y)
Mutation Visual
acuity
Cornea Keratometry
(mm)
Schirmer
(mm 5
min)
IOP
(mm Hg)
Other findings
RE     LE RE       LE RE    LE RE    LE
1 2.IV86 M, 41 - 1.0     1.0 Normal 7,92     7,88
2 2.IV54 F, 44 + 1.0     1.0 Normal Dry eyes
3 2.IV3 F, 46 - 1.0     1.0 Normal 7,74     7,74 17     17 17     17
4 2.IV50 M, 47 + 1.0     1.0 Corneal striae 7,74     7,68 irr
5 2.IV2 F, 48 - 0.3    1.0 Normal 7,82     7,78 5       5 12     12 Anisometropic
amblyopia RE
6 2.IV52 M, 49 - 1.0     1.0 Normal 8,07     8,06 33     11 14     16
7 2.IV48 M, 49 + 0.8     0.9 Corneal striae Dry eyes
8 2.IV39 M, 49 + 1.0     1.0 Normal 7,74     7,68
9 2.IV6 F, 50 - 1.0     1.0 Normal 7,49     7,52 25     20 14     15
10 2.IV46 F, 52 + 0.5     0.5 Corneal striae 7.60     7.79 Astigmatism,
exophoria
11 2.IV4 M, 54 - 1.0     1.0 Normal 7,50     7,53 11     14 20     20
12 2.IV29 F, 55 + 0.9     0.9 Corneal striae 7,60     7,79 irr Corneal arcus
13 2.IV44 M, 57 - 1.0     1.0 Normal 7,82     7,75 13     15 15     15
14 2.IV42 M, 58 - 1.0     1.0 Normal 7,84     7,85 0       1 12     12
15 2.III43 F, 73 + 0.5     0.6 Corneal striae Dry eyes
16 2.III33 M, 74 + 0.6     0.6 Corneal striae irregular Refraction instability
17 2.III24 M, 74 + Corneal striae 7,56     7.56 Incipient cataract
18 2.III2 M, 80 + 0.5     0.8 Normal 7,71     7,90 28     26 17     14 Cataract surgery RLE,
retinal detachment
surgery RE, ectropion
surgery RE
IOP, intraocular pressure; RE, right eye; LE, left eye; irr, irregular; Visual acuity = best corrected visual acuity.
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Family 3
Patient
Code
Gender
Age (y)
Mutation Visual
acuity
Cornea Keratometry
(mm)
Schirmer
(mm 5 min)
IOP
(mm Hg)
Other findings
RE     LE RE       LE RE    LE RE    LE
1 3.IV13 M, 28 - 1.0     1.0 Normal 7,58     7,70 15     15 14     14 Retinal detachment
2 3.IV14 M, 30 + 1.0     1.0 Normal
3 3.IV24 F, 33 + 1.0     1.0 Normal 7,63     7,73 15     15 14     14
4 3.III32 F, 48 + 1.0     1.0 Corneal striae
5 3.III21 M, 50 - 1.0     1.0 Normal
6 3.III19 M, 51 + 0.6     0.6 Corneal striae 7,84     7,53 15     15 15     15 Cataract,
astigmatism LE
7 3.III16 M, 55 + 1.0     1.0 Normal
8 3.III30 M, 55 - 1.0     1.0 Corneal striae 7,92     7,90 2       2 15     15
9 3.III26 F, 55 + 1.0     1.0 Normal 7,52     7,52 15     15 14     14
10 3.III15 M, 56 + 1.0     1.0 Corneal striae
11 3.III11 F, 57 - 1.0     0.1 Normal 7,55     7,59 25     20 19     20 Anisometropicopia,
retinal laser
coagulation
12 3.III6 M, 58 - 1.0     1.0 Normal 7,81     7,79 12     25 12    12
13 3.III8 M, 59 + 0.6     0.6 Corneal striae 7,40     7,51 2       2 15     15 Myopic fundus
14 3.III3 F, 63 - 1.0     1.0 Normal 7,43     7,48 13     7 18     18 Asteroid
hyelopathy, iris cyst
RE
15 3.III1 F, 65 - 1.0     1.0 Normal 8,11     8,20 20     22 14     14
16 3.II16 M, 79 + 1.0     1.0 Normal 18     23
IOP, intraocular pressure; RE, right eye; LE, left eye; Visual acuity = best corrected visual acuity.
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Family 4
Patient
Code
Gender
Age (y)
Mutation Visual
acuity
Cornea IOP
(mm Hg)
Other findings
RE     LE RE    LE
1 4.IV38 F, 26 + 1.0     1.0 Normal 14     14
2 4.IV82 M, 29 + 1.0     1.0 Normal 13     13
3 4.IV81 F, 30 + 1.0     1.0 Normal 12     12 Dry eyes
4 4.IV83 M, 32 + 1.0     1.0 Normal 12     12
5 4.IV80 F, 33 - 1.0     1.0 Normal 12     12
6 4.IV31 M, 34 - 1.0     1.0 Normal 13     12 Exophoria
7 4.IV21 F, 36 + 1.0     1.0 Normal 10     10
8 4.IV27 F, 39 + 1.0     1.0 Normal 12     12
9 4.IV43 F, 39 - 1.0     1.0 Normal 10     10
10 4.IV18 M, 39 + 1.0     1.0 Normal 12     13
11 4.IV17 F, 40 + 1.0     1.0 Normal 13     13
12 4.IV16 F, 41 - 1.0     1.0 Normal 16     14
13 4.IV20 M, 34 + 1.0     1.0 Normal 11     11
14 4.IV19 F, 44 - 1.0     1.0 Normal 11     11
15 4.III83 M, 55 + 1.0     1.0 Normal 12     12 Dry eyes
16 4.III32 F, 56 + 0.8     0.8 Normal 15     15
17 4.III30 F, 58 - 1.0     1.0 Normal 12     12
18 4.III72 M, 59 + 1.0     0.2 Normal 12     13 Dry eyes, bullous keratopathy
19 4.III81 F, 59 + 1.0     0.8 Normal 10     10 Dry eyes, exophthalmos (Graves)
20 4.III25 F, 62 - 1.0     1.0 Normal 13     13 Dry eyes
21 4.III53 M, 63 - 0.6     1.0 Normal 14     13 Incipient cataract
22 4.III77 F, 63 - 1.0     1.0 Normal 14     14 Dry eyes
23 4.III71 F, 64 + 0.3     0.8 Corneal striae RE 12     15 Dry eyes, keratoconus, cataract
surgery LE, corneal
transplantation LE
24 4.III20 M, 67 + 1.0     0.8 Normal 10     10 Strabismus (esotropia) LE
25 4.III49 M, 68 + 1.0     0.8 Normal 12     10
26 4.III39 M, 69 + 0.8     1.0 Normal 12     12
27 4.III18 M, 70 - 0.8     0.8 Normal 12     12 Retinal detachment surgery RE,
cataract surgery
28 4.III16 M, 71 + 0.8     1.0 Normal 12     13 Incipient cataract
29 4.III45 F, 72 + 0.6     1.0 Normal 16     16 Incipient cataract
30 4.III12 M, 74 - 1.0     1.0 Normal 14     12 Incipient cataract
IOP, intraocular pressure; RE, right eye; LE, left eye; Visual acuity = best corrected visual acuity.
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Abstract
Objectives: To report hearing impairment and vestibular and ocular features in a
Dutch DFNA11 family and to compare these results to reported data on three
other DFNA11 families.
Study Design: Family study.
Methods: Regression analysis was performed in relation to age to outline the
development of hearing thresholds and speech recognition scores. Vestibular and
ocular functions were examined.
Results: First symptoms of hearing impairment started between the ages of four
and 43 years. Most of the audiograms were symmetric and flat or downsloping.
The annual threshold deterioration increased from 0.2 to 2.6 dB per year at 0.25 to
8 kHz in the longitudinal analyses and in the cross-sectional analysis from 0.3 to
0.9 dB per year. The speech recognition score was quite good, deteriorating by
0.9% per year from a 90% score at the age of 36 years onwards. Remarkably,
extensive ocular examination including corrected visual acuity and refraction
measurements, slit-lamp examination, ophthalmoscopy, Goldmann perimetry,
electroretinography and electro-oculography revealed signs of subclinical retinal
dysfunction. None of the patients showed the classic triad of retinitis pigmentosa.
Pure-tone thresholds, phoneme recognition scores and vestibular responses of the
mutation carriers were fairly similar to previously described DFNA11 families.
Conclusion: Even though the diverse mutations are located in different regions of
the  myosin  VIIa  gene,  the  cochleovestibular  phenotype  is  fairly  similar  in  all
DFNA11 families. Surprisingly, subclinical retinal dysfunction was detected only
in this family.
Introduction
Since about 15 years, linkage and mutation analysis have been used extensively to
gain insight into the causes of hereditary non-syndromic hearing impairment.
Genetic hearing impairment is heterogeneous. Nowadays, more than 50 loci and
21 genes are known for non-syndromic autosomal dominant forms of hearing
impairment (DFNA). Also, 57 loci and 21 genes have been identified for auto-
somal  recessive  forms  (DFNB).1 In some cases, the same gene is responsible for
syndromic as well as non-syndromic hearing impairment, such as WFS1 for
Wolfram syndrome2 and DFNA6/14/38.3,4 Other genes are involved in both
autosomal dominant and autosomal recessive hearing impairment. Mutations in
the TECTA gene, for example, can cause either DFNA8/12 or DFNB21.5,6
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Mutations in the myosin VIIa (MYO7A) gene cause non-syndromic autosomal
dominant (DFNA11)7,8 and autosomal recessive (DFNB2) hearing impairment,9,10
Usher syndrome Type 1B (USH1B)11 and atypical Usher syndrome.12,13 MYO7A
encodes the protein myosin VIIa and is expressed in the inner ear, retina, testis,
lung,  kidney,  liver,  olfactory  epithelium  and  intestine.14-16 Expression is more
prominent in inner hair cells than in outer hair cells of the cochlea, where the
protein is located in the stereocilia, the cell body and the cuticular plate.14 Myosin
VIIa is also present in Type I and Type II hair cells of the utricle and semicircular
canals. In the eye, this protein has been found in the retinal pigment epithelial
cells and in photoreceptor cells, mainly in the inner, the base of the outer
segments and the synaptic endings.17 In addition, Liu et al. identified myosin VIIa
to be situated in the connecting cilium of photoreceptor cells.18 Myosin VIIa is an
unconventional myosin motor molecule that moves along actin filaments using
actin-activated  ATP-ase  activity  for  its  force  and  motion.  It  is  involved  in  the
organization of the cochlear hair cell stereocilia and is essential for structural
integrity of hair bundles.15 It is also important in the distribution of melanosomes
in the retinal pigment epithelial cells19 and opsin transport in photoreceptor cells20
and is part of the Usher I protein complex.21,22
Four DFNA11 families have currently been described.23-27 Recently a fifth DFNA11
family with a 699 C-to-T transition in MYO7A which leads to an Ala230Val
substitution in the motor domain, was presented by poster.28 The present report
describes the results of audiovestibular and ocular examinations of affected family
members in the Dutch DFNA11 family. Luijendijk et al. previously reported on an
Asn458Ile mutation in the motor domain of myosin VIIa that causes DFNA11 in
this family.25 Pure-tone and speech audiometric data were analysed and
compared with the results described for the other DFNA11 families.23,24,26,27
Patients and Methods
Patients
Twenty-six individuals of the Dutch DFNA11 family (W02-011) participated in
this study. Signed informed consent was obtained from all participants. The study
was approved by the local medical ethics committee. Medical history was taken,
with emphasis on hearing impairment and vestibular and ocular symptoms. Non-
hereditary causes of hearing impairment were excluded.
Blood samples were obtained for linkage and mutation analysis. Guided by the
phenotypic features, linkage analysis for DFNA11 confirmed linkage to the locus
of MYO7A. Mutation analysis of MYO7A revealed a c.1373A>T nucleotide
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substitution in exon 13, which is predicted to cause an Asn458Ile amino acid
substitution in the motor domain of myosin VIIa.25
Audiovestibular examination and analysis
All participants underwent otologic examination. Pure-tone and speech
audiometry were performed in a sound-treated room, according to common
clinical standards. Vestibular examination, carried out as previously described,29
was performed in six affected mutation carriers. Binaural mean pure-tone
threshold  levels  were  calculated  for  each  frequency.  Longitudinal  and  cross-
sectional analyses were performed for each frequency separately, using linear
regression analysis. Longitudinal analysis covered the cases with sufficient serial
audiograms. Cross-sectional analysis included the threshold data of the single-
snapshot measurements as well as the mean threshold-by-age values derived for
the longitudinal cases. Slope was called annual threshold deterioration (ATD),
expressed in dB per year. When the 95% confidence interval for slope did not
include zero, slope (or ATD) was labelled as significant. Because the longitudinal
regression lines generally could not be pooled according to an analysis similar to
analysis of covariance (ANCOVA, Prism PC Version 3; GraphPad, San Diego CA,
U.S.A.), a trend line was drawn for each frequency on the basis of median slope
and intercept values. The longitudinal and cross-sectional trend lines were used to
construct two different sets of age-related typical audiograms (ARTA).30 To
compare audiologic results between the present and the other DFNA11 families,
ARTA  were  also  derived  for  the  Japanese  and  the  American  families,  using
available cross-sectional data.23,26
Speech audiometry was performed with a standard phonetically balanced Dutch
word list. Maximum monaural phoneme recognition scores were derived from
individual performance-versus-intensity plots. Cross-sectional recognition scores
averaged for both ears were plotted against age and binaural mean pure-tone
average (PTA1,2,4 kHz) in decibels hearing level (HL). Onset age and onset level were
identified at a maximum phoneme recognition score of 90% in the performance-
versus-age and performance-versus-impairment plots. The slope was called
deterioration rate and deterioration gradient, respectively.31 Only speech
recognition scores of the Japanese family were available for comparison of speech
deterioration between the DFNA11 families.23
Ocular examination
In five clinically affected mutation carriers, ocular examinations consisting of
corrected visual acuity and refraction measurements, slit-lamp examination,
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ophthalmoscopy and Goldmann perimetry were performed to detect signs of
retinitis pigmentosa. Additional ophthalmologic tests included electroretino-
graphy (ERG) and electro-oculography (EOG), which were performed and
evaluated according to the International Society for Clinical Electrophysiology of
Vision Standards.32,33 Intraocular pressure measurements (applanation tonometry)
and keratometry readings were also obtained.
Figure 1. Part of the pedigree of the present DFNA11 family. Square, man; circle, woman;
filled symbol, affected person; open symbol, not affected; arrow, proband. The hearing
status of individual II:5 was unclear. Mutation analysis showed that this person was not a
mutation carrier.
Results
The pedigree  (Figure  1)  comprised 11  affected family  members.  Both spouses  in
the first-generation marriage had severe hearing impairment, which complicated
the genetic analysis. The hearing status of individual II:5 was not completely clear.
Audiometric data coincided with the individual 95th percentile threshold values of
presbyacusis (P95).34 Mutation analysis showed that this person was not a
mutation carrier.25 Except for mild noise exposure in two cases (III:1 and III:5), no
other causes of hearing impairment were noticed in this family. First symptoms of
hearing impairment were dated between the ages of four and 43 years, whereas
affected individual II:7 reported the first symptoms at 63 years of age.
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Figure 2 (A-I). Audiograms of the nine affected family members ordered by age at last
visit.
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Four persons also reported having tinnitus. Otoscopic examination was normal in
all affected individuals. Pure-tone audiograms (Figure 2) were fairly symmetric
with moderate to severe hearing loss. The threshold configuration was variable.
The pattern was fairly flat at 0.25 to 4 kHz in three individuals (Figure 2B, 2G,
2H), whereas a low-frequency (i.e. a generally ascending configuration) was seen
in  three  other  individuals  (Figure  2  D-F).  In  the  last  three  individuals  it  was,  or
eventually became, gently (Fig 2A) or steeply (Figure 2C, 2I) downsloping.
Siblings II:1 and II:7, as well as siblings III:1,3,5 and siblings III:22,24 showed
remarkable differences in reported onset age and/or severity of hearing
impairment.
Audiometric analysis
Figure 3 shows longitudinal data of six cases with their regression lines and trend
lines.  The  ATD  increased  from  0.2  dB  per  year  (0.25  kHz)  to  2.6  dB  per  year  (8
kHz). Most of the individual regression lines showed significant progression at
the high frequencies. Progression by 2.6 dB per year at 8 kHz certainly implies
progression beyond (median) presbyacusis.
Figure 4 shows a cross-sectional plot of both the three single-snapshot cases and
the mean threshold of the longitudinal cases plotted at the mean age for each
frequency  together  with  the  calculated  regression  line.  Equal  weights  were  thus
assigned to all data points, no matter whether they pertained to single-snapshot
or longitudinal measurements. The ATD increased from 0.3 dB per year (0.25
kHz) to 0.9 dB per year (8 kHz). There was no significant progression at any
frequency.
Fisher’s exact test was used to test for the possible presence of ascertainment bias
in the cross-sectional data. Relative to an arbitrary imaginary dividing line (close
to the regression line), the counts of data points representing longitudinal or
single-snapshot cases were entered in a 2x2 contingency table. The single-
snapshot measurements represented a cluster of threshold values that were
significantly lower than those pertaining to the longitudinal cases, except for 8
kHz. This suggests the presence of an ascertainment bias: subjects who had
presented themselves or had been referred as a patient for repeated
measurements can be associated with more severe and progressive hearing
impairment than subjects who had audiometry only once (Figure 4).
There was an obvious discrepancy between the results obtained from the
longitudinal (Figure 3) and the cross-sectional analyses (Figure 4): the former
indicated more progression than the latter.
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Figure 3. Longitudinal analysis of binaural air conduction thresholds (in decibels hearing
level) versus age (in years). Individual longitudinal data (open circles) of six mutation
carriers with connecting hairlines are plotted for the frequencies 0.25 to 8 kHz. The
longitudinal regression lines are included; boldface lines indicate significant progression.
The trend lines (dotted) are added to show the ATD per frequency. ATD and intercepts
are indicated in boldface figures.
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Figure 4. Cross-sectional analysis of the nine mutation carriers of the present family;
threshold data of the single-snapshot cases (three cases, filled circles) with the mean
threshold and age values derived for the longitudinal cases (six cases, open circles).
Regression analysis with ATD and intercepts indicated in boldface type.
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This  was  attributed  to  inclusion  of  the  single  snapshots  in  the  cross-sectional
analysis  (Figure  4)  and  the  observation  of  fairly  similar  progression  in  different
individuals, apparently showing largely different onset ages (Figure 3).
Figure 5. ARTA based on cross-sectional analyses of the present family (A) and derived
from cross-sectional data reported for the Japanese and the American DFNA11 families (B
and C), respectively. Italics indicate age in decade steps. Thin lines in panels A and B
indicate absence of threshold estimated age in panel C.
Figure 5 shows the ARTA derived from the cross-sectional analyses of the present
family (Figure 5A), together with the ARTA based on the cross-sectional data of
the Japanese family (Figure 5B) and the American family (Figure 5C).23,26 The
results of attempted longitudinal analyses were fairly comparable to those of the
cross-sectional analysis in these families, but the numbers of longitudinal data
were limited. The ARTA of the present family (Figure 5A) show a fairly flat
threshold curve at  young ages  and only  modest  progression,  most  clearly  at  the
high frequencies. The ARTA of the Japanese family (Figure 5B) are quite similar to
that of the Dutch family, with less progression in the high frequencies. The ARTA
of the American family (Figure 5C) are also fairly similar, with slightly more
progression. Speech recognition was remarkably well preserved in the present
family, with a score of 50% correct still present at 80 years of age. From an onset
age (i.e. 90 % score) of 36 years onwards, the speech recognition score declined at
a deterioration rate of 0.9% per year (Figure 6 A). Figure 6 B shows the binaural
mean speech recognition score as a function of binaural mean PTA1,2,4 kHz, with an
onset level (i.e. 90 % score) of 51 dB HL, decreasing by 0.8% per dB. Speech
recognition scores in the present family were comparable to those reported for the
Japanese family; only the deterioration gradients were significantly different
according to ANCOVA (Figure 6, Table 1). There were no reports on speech
recognition in the other families.
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Figure 6. Cross-sectional binaural mean speech recognition scores (% correct) of the
Dutch and Japanese families at last visit against age (in years) (A) and binaural mean
PTA1, 2, 4 kHz (in decibels hearing level) (B). Open circles and bold line, Dutch family; filled
circles and thin line, Japanese family. The dashed (Dutch family) or dotted (Japanese
family) lines with bold number indicate onset age (A) and onset level (B). Numbers near
the regression line indicate deterioration rate (A) and deterioration gradient (B).
Table 1. Comparison of clinical and genetic data of all DFNA11 families
Present family25
nr: W02-011
Tamagawa et al. 23,24 Bolz et al. 27 Street et al. 26
nr: HL2
Nucleotide change Asn458Ile Ala886_Lys888del Arg853Cys Gly722Arg
Location Motor domain Coiled coil region IQ5 domain Motor domain
Onset age (y) 4-43 12-16 Childhood 20-30
Audiogram l.f.?flat?downsloping Flat?  downsloping Not available l.f.?flat?downsloping
ATD/progression 0.3-0.9 dB per y* mean: 0.56 dB per y* Slow Present
Vestibular symptoms 4 of 6 patients Absent Not available Absent
Vestibular dysfunction 4 of 6 patients 3 of 5 patients 1 of 5 patients Not available
Retinal dysfunction Subclinical Absent Absent Absent
Speech:
Age of onset (y) 36 34
Deterioration rate (% / y)     0.9 0.7
Level of onset (dB HL) 51 48
Deterioration gradient
(% per dB HL)
0.8 1.0
del, deletion; l.f., low frequency; nr, number; y, years; dB, decibel; HL, hearing level; *, derived
from cross-sectional data.
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Vestibular examination
Vestibular examination was performed in six mutation carriers, aged 23 to 78
years. Two individuals had no vestibular symptoms and normal vestibular
responses (III:5 and III:22). Vestibular symptoms, such as vertigo and unsteady
walking, especially in the dark, were present in four individuals. Spontaneous
nystagmus was not observed. The oldest person (II:1) showed vestibular areflexia.
Remarkably, only two years previously she had had a vertigo attack for the first
time. The youngest person (IV:4, proband) showed mild hyporeflexia of the
velocity-step response, with borderline low caloric responses. Hyporeflexia of the
rotatory responses with bilateral caloric weakness was found in the other two
individuals, III:1 and III:3, of which the former had more severe and asymmetric
vestibular dysfunction.
Ocular examinations
Ocular symptoms were not reported. Nobody complained about night blindness.
The results of ocular function tests are presented in Table 2. Corrected visual
acuity was subnormal in carrier II:1, caused by cataract. Intraocular pressures and
keratometry readings were normal. Ophthalmoscopy showed little dots of
pigmentation  in  the  fundus  periphery  in  one  person  (III:5),  but  no  bone-spicule
pigmentations were present. Signs of typical retinitis pigmentosa, such as
arteriolar attenuation and optic disc pallor, were not found. Goldmann perimetry
showed a generally decreased sensitivity in individual II:1 and an enlarged blind
spot in three persons (III:3, III:5 and IV:4). Also, individual III:5 had a relative
scotoma in the temporal visual fields of both eyes. A contraction of both nasal
visual fields was seen in individual IV:4.
Table 2. Ocular examination of 5 mutation carriers of the present family
Mutation
Carrier;
(sex/age)
Eye Visual
Acuity
Fundus Visual field EOG
Lp/Dt
Cone-ERG Rod-ERG Conclusion
II-1
E, 80 y
R
L
0.8
0.6
Normal
Normal
? Sensitivity
? Sensitivity
1.8
1.6
Normal
Normal
Normal
Normal
Mild RPE involvement
Mild RPE involvement
III:1
M, 54 y
R
L
0.8
1.2
Normal
Normal
Normal
Normal
2.1
2.1
Normal
Subnormal
Subnormal
Subnormal
PR involvement
PR involvement
III:3
M, 53 y
R
L
1.0
1.0
Normal
Normal
? Blind spot
? Blind spot
1.9
1.9
Normal
Normal
Normal
Normal
Normal
Normal
III:5
M, 51 y
R
L
1.0
1.0
Pigment
Normal
Temporal scotoma
Temporal scotoma
1.9
2.2
Abnormal
Abnormal
Abnormal
Abnormal
PR involvement
PR involvement
IV:4
F, 24 y
R
L
1.0
1.2
Normal
Normal
? Blind spot
? Blind spot
2.7
2.5
Normal
Normal
Normal
Normal
Normal
Normal
R,  right  eye;  L,  left  eye;  F,  female;  M,  male;  Pigment.,  Pigmentation;  EOG,  electro-oculography;  ERG,
electroretinography; RPE, retinal pigment epithelium; PR, photoreceptor; y, years; Lp/Dt, light peak/dark
trough ratio.
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The EOG light peak/dark trough ratio was abnormal (< 1.9) in one person (II:1),
corresponding to mild involvement of the retinal pigment epithelial cells. The
ERG  results  were  subnormal  in  two  individuals  (III:1  and  III:5).  This  might
suggest subclinical involvement of retinal photoreceptor cells in these two
brothers, however, typical retinitis pigmentosa was not seen.
Discussion
The clinical features of a Dutch family with a MYO7A mutation causing DFNA11
are presented in this study. Hearing impairment was symmetric and progressed
by 0.2 to 2.6 dB per year according to the longitudinal analyses. Cross-sectional
analysis showed a more constant, milder progression over all frequencies of 0.3 to
0.9 dB per year. Subjective onsets varied between childhood and 43 years of age,
with one exception of age 63 years. Variability in onset age and severity was seen
across affected family members. Speech recognition scores were relatively good,
with an onset age of 36 years and a deterioration rate of 0.9% per year.
Recognition scores decreased by 0.8% per dB threshold increase, from a PTA1,  2,  4
kHz of 51 dB HL onward.
Comparison of the data of the present DFNA11 family with those reported for the
other DFNA11 families showed pure-tone and speech audiometric data to be
fairly similar. The range in onset ages was relatively wide compared with the
other families (Table 1). Variability in onset age and severity across affected
family members was observed in the present and the American family.25,26 As
compared with USH1B and DFNB2, sensorineural hearing impairment was mild
to moderate in all families, with minor progression. The audiometric
configuration varies between fairly flat to gently downsloping, or more steeply
downsloping at advanced ages in all three available families. In addition, some
members of the present and of the American family (initially) showed low-
frequency characteristics.25,26 Four members of the present family reported having
tinnitus. In the other families, only one Japanese mutation carrier had tinnitus.24
All  three  sets  of  ARTA  were  fairly  similar,  based  on  the  comparison  of  cross-
sectional analyses.24,26 The American family seemed to have a slightly higher
progression, which was most pronounced at the high frequencies.26
Vestibular dysfunction in the present family is not fully penetrant. It varied from
normal function in two persons (aged 42 and 50 years) to complete vestibular
areflexia in one person (aged 79 years). It seems likely that vestibular impairment
is  progressive,  but  the  number  of  observations  was too small  to  confirm this.  In
the other families, only one person had vestibular symptoms.27 Tamagawa et al.
Chapter 4.1
123
reported no vestibular symptoms. Nevertheless, three of five patients had
spontaneous nystagmus and caloric hypofunction.23,24 In the German family, mild
vestibular dysfunction was found in one person.27 Thus,  in  the  present  family,
more pronounced vestibular failure has been recorded than in the other DFNA11
families.
Ocular symptoms, including night blindness, were not reported in the present
family. Ophthalmoscopy showed little dots of pigmentation in the fundus
periphery in one person. Goldmann perimetry was abnormal in four individuals.
The  EOG  light  peak/dark  trough  ratio  was  abnormal  in  one  person  and  ERG
values were subnormal in two individuals. These findings might suggest
subclinical involvement of both retinal pigment epithelial cells and retinal
photoreceptor cells. Similar findings were not reported in the other families. In the
Japanese family, visual acuity tests, ophthalmoscopy, intraocular pressure
measurements and slit-lamp examination were performed on five carriers and
ERG on four  affected persons.  In  the  American family,  fundus examination was
performed  on  two  mutation  carriers  and  in  the  German  family  ERG,  fundus
examination and dark adaptation studies were performed on four affected
persons.26,27 Because of the limited data, subclinical signs of retinal abnormalities
that remained unnoticed in the other families cannot be excluded.
In the present family, a 1373 A-to-T transversion in exon 13 was found that leads
to an Asn458Ile substitution in the switch II ?-helix of myosin VIIa.25 A molecular
model  of  myosin  VIIa,  based  on  the  structure  of  myosin  II  heavy  chain  from
Dictyostelium discoideum, predicted the Asn458Ile substitution to be responsible for
the hearing impairment. The differently shaped side chain of isoleucine at
position 458 is presumed to cause important structural changes in the motor head
domain.  This  is  believed  to  disrupt  ATP/ADP  binding  and/or  impair  the  power
stroke.25
The Japanese DFNA11 family7,23,24,35 carries an in-frame-9-bp deletion in exon 22 of
MYO7A, leading to the loss of three amino acids (Ala886_Lys888del) in the coiled-
coil domain of the protein.8 In the American family, a c.2164G>C mutation is
present in exon 17, leading to a Gly722Arg nucleotide substitution in the motor
domain of the protein.26 In the German family, a c.2557C>T mutation in exon 21
causes a substitution of cysteine for arginine at residue 853 in the fifth IQ motif.27
Although the four different mutations in MYO7A affect three different domains of
the expressed protein, the clinical presentation of the families is fairly similar. This
is  difficult  to  explain  with  regard  to  what  is  known  about  the  function  of  these
protein domains.
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Up to now, a dominant negative effect was suggested through, for example,
improper dimerization of the aberrant protein in the Japanese family23 and
through correct dimerization that also impairs the function of the wild-type
proteins.25-27 One might suggest that all DFNA11 mutations reduce the stability of
the protein, as suggested by the results of Rhodes et al. for the headbanger mouse.
However, the reduction in levels of myosin VIIa36 does not explain why carriers of
truncating mutations that are causative for Usher syndrome Type 1B have no
symptoms and signs of hearing impairment,37 unless  dimerization  with  mutant
myosin VIIa causes a dominant negative effect. This would then result in less than
50% of the normal protein level causing cochleovestibular and retinal dysfunction,
whereas 50% of normal protein causes no dysfunction in carriers of Usher
syndrome Type 1B.
It is interesting to compare the clinical presentations of DFNA11 and USH1B.
Usher syndrome Type I is characterized by congenital profound hearing
impairment, with sparing only of residual hearing at the lower frequencies,38
together with vestibular areflexia and prepubertal retinitis pigmentosa.39 DFNA11
patients have mild to moderate progressive hearing impairment and vestibular
dysfunction associated with subclinical retinal abnormalities in the present family.
Carriers of Usher Type 1B showed ophthalmologic abnormalities as well, but had
normal hearing.37,40 However, the genetic diagnosis was based on gene linkage
results, as mutation analysis on MYO7A was not performed by that time.
Conclusion
In summary, we found fairly similar cochleovestibular phenotype in all DFNA11
families with subclinical retinal abnormalities exclusively in the present family.
Investigations with in vivo models will be needed to reveal the mechanisms
involved in DFNA11 and myosin VIIa.
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Discussion
The principal aim of this thesis was to contribute to our knowledge on phenotype-
genotype correlation in autosomal dominant types of non-syndromic hearing
impairment:  DFNA5,  DFNA9  and  DFNA11.  In  the  chapters  of  this  thesis  the
clinical features of the investigated families have been described in relation to the
genotypes. Other families, in which genetic analysis has not been successful yet,
are  not  included  in  this  thesis.  Two  new  mutations  have  been  identified  in  the
DFNA5 and the DFNA11 families, of which the latter has been reported by
Luijendijk et al.1 Detailed audiometric analyses of the DFNA5, DFNA9 and
DFNA11 families have been made and they have been compared with other
families  described  in  the  literature,  where  possible.  It  is  very  important  to
evaluate if the phenotypes are (dis)similar in families with different mutations in
the same gene for a more specific diagnosis and better counselling.
In chapter 2, a DFNA5 family is described and the phenotype has been compared
to that of the original family.2 The  phenotype  of  a  third  DFNA5  family  was  not
available during the preparation of this article for a distinct comparison with the
other families.3 All three known families showed a similar phenotype with
progressive sensorineural hearing impairment starting in the high frequencies,
with better speech discrimination in the family described in the present article.
Although the mutations are different in all families, they have the same effect on
the mRNA, namely skipping of exon 8. This suggests that these DFNA5 mutations
are “gain of function” mutations that lead to a truncated protein with a
deleterious novel function. Studies by Van Laer et al.4 supported this by
demonstrating significantly increased necrotic cell death in mammalian HEK293T
cells transfected with mutant DFNA5 compared to cells transfected with wild-type
DFNA5. Although DFNA5 expression is present at low levels in multiple tissues,
only  progressive  hearing loss  occurs  in  mutation carriers.  This  can be  explained
by a larger susceptibility of cochlear cells to the damaging actions of mutant
DFNA5,  because  DFNA5  might  interact  with  cellular  components  that  are  only
expressed in cochlear cells.4
The cochleovestibular phenotype of DFNA9 patients with the Pro51Ser mutation
in the COCH gene is comparable. Hearing impairment develops from the fourth
to fifth decade, similar to the phenotype of the following mutations in the COCH
gene: Gly87Trp, Gly88Glu, Val104del, Ile109Asn, Ile109Thr, Ala119Thr, and
Cys542Phe.5-13 In contrast, it starts in the second to third decades in the American
families with the Val66Gly and Trp117Arg mutations.5,14 Different from other
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COCH mutations,11,12 the vestibular dysfunction starts almost a decade before the
hearing impairment begins in patients with the Pro51Ser mutation.
In chapter 4, a DFNA11 family has been described and the phenotype has been
compared to that of three other DFNA11 families. 15-18 A  fifth  family  was  not
described at the time.19 Although the mutations in myosin VIIa were different in
all  families,  the  inner  ear  phenotype  was  similar.  Patients  suffered  from
sensorineural hearing impairment with steady progression at all frequencies and
vestibular dysfunction. However, the vestibular function was intact in the family
described by Street et al.18
In DFNA9 and DFNA11 two ophthalmologic features are described that have not
been observed before. The subtle subclinical retinal abnormalities that are shown
in the investigated DFNA11 family might be faint reflections of retinitis
pigmentosa, which is seen in Usher syndrome Type IB. Mutations in the same
gene  also  cause  DFNB2,  in  which  no  retinal  abnormalities  are  present.  It  is  still
unclear how deficiency of functional myosin VIIa leads to retinal dysfunction in
Usher Type 1B and the present DFNA11 family and why there are no retinal
features in DFNB2 and in the other three known DFNA11 families described in
the literature. Retinal degeneration has not been diagnosed in the shaker-1 mouse
model and the Usher Type 1B rat model (Myo7atnd-1Hubr).20,21 However, some retinal
abnormalities have been found, such as a decreased amplitude in
electroretinography of shaker-1 mice,22 abnormal  opsin  accumulation  in  the
connecting cilium and reduction of photoreceptive disk membrane renewal rate in
shaker-1 mice23 and absence of melanosomes in the apical processes of the retinal
pigment  epithelium  in  both  animal  models.21,24 Further investigations will be
necessary to clarify this subject, especially in the headbanger mice with an
autosomal dominant mutation Myo7a were  no  attention  was  paid  to  possible
retinal features.25
The characteristic vertical corneal striae found in three DFNA9 families with the
Pro51Ser and the Gly88Glu mutation in the COCH gene  cannot  easily  be
explained. We propose that this corneal feature and the cochleovestibular
dysfunction  are  caused  by  these  two  mutations  in  the COCH gene.  This  is
supported by the detection of co-deposits of cochlin and acidophilic
mucopolysaccharide in the trabecular meshwork of patients with primary open
angle glaucoma and in glaucomatous DBA/2J mice with progressive hearing
loss.26,27 Other evidence to support the causative relationship is the identification
of COCH transcripts in the human cornea using RT-PCR (Chapter 3.2) and in a
cDNA library constructed using RNA from the anterior segment of the zebrafish
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eye.28 Additional investigations of the other DFNA9 families with different
mutations will be required to strengthen this theory.
Hereditary non-syndromic hearing impairment is quite heterogeneous. New
types of hereditary non-syndromic hearing impairment have been reported
almost every month. About 125 non-syndromic autosomal dominant and
autosomal recessive types have been identified in approximately 15 years and by
now, 39 causative genes are known. The increasing understanding of the genes
involved will provide more and more insight into the molecular mechanisms that
underly the processes of normal hearing and hearing impairment. The genes
known today encode a variety of proteins, including extracellular matrix proteins,
motor molecules, gap junction proteins, transcription factors and ion channels.
The function of several proteins known to be involved in sensorineural hearing
impairment is still unknown, such as DFNA5 (in DFNA5), wolframin (in
DFNA6/14/38 and Wolfram syndrome) and TMC1 (in DFNA36).
With the completion of the Human Genome Project in 2003, the field of genetic
medicine is experiencing an essential transformation. The identification of our
genes and the proteins they encode and the knowledge of the pathologic
mechanisms of the mutations will contribute tremendously, the developments in
diagnosis, treatment and prevention of hereditary diseases. Such knowledge will
make gene therapy possible for hearing impaired patients in the future, but for
now, we only have hearing aids and cochlear implants to offer. Gene therapy
comprises  the  introduction of  normal  genes  into  human somatic  or  stem cells  to
treat  a  specific  disorder.  Because  the  cochlea  is  a  very  small  organ,  which  is
difficult to reach, the development of a successful gene delivery method is
challenging. There are non-viral vectors, such as liposomes, and viral vectors, for
instance adenovirus, adeno-associated virus, herpes simplex virus and lentivirus
vectors.29 Viral  vectors  use  their  infectivity  to  launch and express  the  exogenous
genes that have been inserted in the viral genome. Adenovirus vectors are being
used most widely at this moment. It  is effective at many sites of the cochlea. An
unfortunate side effect is a strong immune response, which can cause a toxic effect
on the recipient cell. This can, however, be treated by immunosuppression.29 An
additional problem is the limited duration of expression, because the adenovirus
does not integrate in the human genome.29 It  is  important  to  develop  a  method
that delivers vectors into the cochlea without damaging the cochlear architecture,
causing hearing impairment. Several methods have been examined, including
osmotic minipump infusion or microinjection into the scala tympani via the round
window30-32 or through a cochleostomy in the basal turn of the cochlea33,34 and
Discussion and Summery
134
injection  into  the  endolymphatic  sac  and  even  into  the  posterior  semicircular
canal.34,35 The least invasive technique has been application of gelfoam soaked
with therapeutic agent to the round window membrane.36
Another difficulty for gene therapy is synthesis and accumulation of aberrant
proteins, which causes irreversible damage. This occurs in particular in autosomal
dominant types of hearing impairment. To prevent this, gene therapy at an early
stage would be necessary. Additionally, if there is a dominant negative
mechanism, the expression of the mutant protein has to be stopped, to make gene
therapy successful. Maeda et al. have succeeded to silence the expression of the
mutated GJB2 gene in vivo using short interfering RNA, which protects normal
hearing.37
Gene therapy is more easily achieved with autosomal recessive diseases, where
the  insertion  of  a  normal  gene  will  replace  the  absent  product.  It  has  been
effectively applied to the mouse model of DFNB3, the shaker-2 mouse model.
Insertion of a bacterial artificial chromosome transgene containing the Myo15a
gene into homozygous shaker-2 mice maintains normal cochlear structure and
function and excess of Myo15a does not induce a toxic effect.38
Stem cell therapy is another challenge. Mammals cannot regenerate auditory hair
cells as lower vertebrates can. Genomic tools are being used with the aim to
decipher the molecular basis of this regenerative capability. For hearing
restoration it is needed to not only produce functional hair cells, but also to
integrate them into appropriate neural pathways. Another challenge is to
structure the cell growth and prevent uncontrolled production of cells leading to
tumour growth. It is clear that it will take many years before gene therapy on the
inner ear will be applied in a clinical setting.
Summary
Chapter 1 begins with a general introduction of hereditary hearing impairment.
In table 1, the phenotype and genotype of all known DFNA-types are described,
together  with  all  identified  mutations.  Finally,  an  up  to  date  review  is  given  on
DFNA5, DFNA9 and DFNA11.
Chapter 2 describes the clinical and genetic evaluation of a Dutch DFNA5 family
with non-syndromic sensorineural hearing impairment and compares the clinical
data with the first Dutch DFNA5 family.2 Because  our  article  was  published
almost simultaneously with that of the Chinese DFNA5 family,3 we could not
compare these two families. Sensorineural hearing impairment was non-
Chapter 5
135
syndromic and symmetric with predominance in the high frequencies. Subjective
hearing impairment arose from 0 to 40 years. Audiometric analyses showed a
congential hearing loss of 30 dB in the high frequencies. The hearing loss was
most progressive at 0.5 and 1 kHz. Pure-tone and speech audiometric data were
compared to the data of the first DFNA5 family. 2 The present DFNA5 family has
similar hearing impairment as the original family in terms of pure-tone
thresholds, but with more favourable speech. Due to resemblance in audiometric
data with the first DFNA5 family, linkage analysis was found with markers
flanking the DFNA5 gene.  Mutation  analysis  revealed  the  presence  of  a DFNA5
mutation  causing  a  C-to-G  nucleotide  transversion  in  the  splice  acceptor  site  of
intron 7. This leads to skipping of exon 8 in part of the transcripts.
The relatively low amount of the aberrant gene transcript in the present family
suggests that a dominant negative effect of the mutant protein causes the hearing
loss. Because the abnormal splicing product has been found in higher levels in the
first  family  and  is  also  present  at  very  low  levels  in  controls,  there  might  be  a
critical threshold for the aberrant protein above which it becomes pathogenic.
Whether the differences in speech recognition between the two families are due to
the different ratios of normal versus aberrant protein remains to be clarified.
Chapter 3 presents cochleovestibular and ocular features of DFNA9. In Chapter 3.1
a clinical report on cochleovestibular impairment of a family with the Pro51Ser
mutation in the COCH gene has been described, after which a detailed analysis
has been made of 74 mutation carriers with the same gene defect. The vestibulo-
ocular reflex, plotted against age, was compared with the pure tone average at 1, 2
and 4 kHz, plotted against the same parameter. Vestibular dysfunction appeared
to have a 100% penetrance. We concluded that vestibular impairment starts about
nine years earlier, progresses more rapidly and eventually, is more complete than
hearing impairment in Pro51Ser mutation carriers. At the time that the hearing
impairment had just started, which is at the age of 43 years, the vestibular
dysfunction was already almost complete.
In Chapter 3.2 a significant association of DFNA9 and peculiar vertical corneal
striae is described in three DFNA9 families with two different mutations in the
COCH gene.  The examinations were performed on a total of 98 family members
with 61 mutation carriers of four families. Families 1 (Chapter 3.1) and 2 harbour
the Pro51Ser mutation and families 3 and 4 harbour the Gly88Glu and the
Gly87Trp mutation, respectively. The vertical corneal striae caused minor
problems,  as  dry  eye  symptoms,  and  were  not  present  in  the  general  Dutch
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ophthalmologic population. The striae were present from an age of 47 years in 32
individuals, of whom 27 individuals had a COCH mutation. Statistical analysis on
the striae and the COCH mutations showed a significant association in families 1,
2 and 3, but not in family 4. Although five individuals without the mutation have
the vertical cornea striae and there is no association in family 4, a sequence variant
in a neighbouring gene causing cosegregation of the two features is unlikely.
Because the striae are present in three DFNA9 families with two different COCH
mutations and the vertical corneal striae are not present in the ophthalmologic
population, we propose that the Pro51Ser and the Gly88Glu mutations in the
COCH gene cause both the vertical corneal striae and the cochleovestibular
dysfunction. This is supported by the detection of transcripts of the COCH gene in
the  human cornea and in  a  cDNA library constructed from RNA of  the  anterior
segment of the zebrafish eye.28 In  addition,  cochlin  has  been  detected  in  the
trabecular meshwork of patients with primary open angle glaucoma.
Accumulation of this protein with eosinophilic glycosaminoglycans has been
found in both the cochlea and the anterior part of the eye.26, 39
A Dutch DFNA11 family is presented in Chapter 4. Mutation analysis revealed a
c.1373A>T nucleotide substitution in exon 13, that is predicted to cause an
Asn458Ile amino acid substitution in the motor domain of myosin VIIa.1
Subjective hearing loss was initiated between the ages of four and 43 years. The
hearing impairment pattern was flat or lightly downsloping. Subclinical
abnormalities were found in Goldmann perimetry, electro-oculography and
electroretinography. This points to subtle dysfunctions of the photoreceptor cells
and retinal pigment epithelial cells in the retina. Cochleovestibular and ocular
features were compared to data on three other DFNA11 families.15-18 A fifth family
was not described at the time.19 Although the four known DFNA11 mutations in
the MYO7A gene affect three different domains of the protein, the inner ear
phenotype was found to be fairly similar in all DFNA11 families. Nevertheless, no
retinal abnormalities were found in the other DFNA11 families. Mutations in
MYO7A can  cause  Usher  syndrome  type  IB,  DFNB2  and  DFNA11.  In  Usher
syndrome type IB visual impairment due to retinitis pigmentosa is a main feature,
together with congenital profound hearing loss. Retinal dysfunction has not been
reported in DFNB2. Remarkably, delicate subclinical retinal involvement of both
photoreceptor cells and retinal pigment epithelial cells was detected in the present
DFNA11 family, while this was not found in the other DFNA11 families.
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Samenvatting
Het hoofddoel van dit proefschrift is het ontwikkelen van kennis over het klinisch
beeld bij families met een bepaald type niet-syndromale autosomaal dominant
overervende slechthorendheid, bekend als “DFNA”: DFNA5, DFNA9 en
DFNA11. Audiometrische en vestibulaire data werden verzameld en
geanalyseerd om zo specifiek mogelijk het fenotype te karakteriseren.
Bloedmonsters werden genomen voor genkoppeling-onderzoek en
mutatieanalyse om het genotype te identificeren. Tevens werden andere klinische
kenmerken zoals spraakherkenning onderzocht. Bij DFNA9 en DFNA11 werd ook
oogheelkundig onderzoek verricht om mogelijk aanwezige subklinische
afwijkingen te kunnen opsporen. Vervolgens werden de klinische data vergeleken
met de data van andere families met hetzelfde DFNA-type. De zorgvuldige
beschrijving van het fenotype in vergelijking met het genotype is van belang voor
een goede classificatie en klinische diagnostiek van erfelijke slechthorendheid. Het
bespaart tijd en daarmee kosten om voor een bekend locus genkoppeling en/of
mutatie-analyse te kunnen toepassen op basis van de klinische diagnostiek, zodat
een volledige diagnostische screening van het genoom niet nodig is. Er is een
enorme toename ontstaan in kennis over de verschillende genen die betrokken
zijn bij slechthorendheid en de heterogeniteit van erfelijk gehoorverlies is
aanzienlijk. Het bestuderen van de klinische kenmerken is daarmee van betekenis,
om op basis van het fenotype het vermoedelijke genotype te leren kennen. In de
laatste 15 jaar zijn er maar liefst 54 loci en 21 genen geïdentificeerd voor niet-
syndromale, autosomaal dominant overervende slechthorendheid. Een verdere
uitbreiding van het aantal DFNA loci tot wel 100 is in de nabije toekomst te
verwachten. Een ander klinisch belang van deze studies is om patiënten die aan
een erfelijke aandoening lijden en hun familieleden nauwkeurig en uitgebreid te
kunnen informeren. Al deze kennis over de betrokken genen, de functie van het
eiwit en het pathologische mechanisme veroorzaakt door de mutaties, zal een
buitengewone bijdrage leveren aan behandeling en preventie van erfelijke
aandoeningen in de toekomst.
Hoofdstuk 1 is een algemene inleiding over erfelijke niet-syndromale slechthorend-
heid.  In  tabel  1  wordt  het  fenotype en genotype van alle  autosomaal  dominante
vormen van slechthorendheid vermeld. Dit is de meest “actuele” tabel waarin ook
alle mutaties staan vermeld. Vervolgens wordt een overzicht gegeven over
DFNA5, DFNA9 en DFNA11.
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Hoofdstuk 2 beschrijft de klinische en genetische evaluatie van een DFNA5 familie
met niet-syndromale sensorineurale slechthorendheid en vergelijkt de klinische
data met de originele DFNA5 familie.1 Tijdens het schrijven van het artikel was de
derde DFNA5 familie uit China nog niet gepubliceerd, waardoor de data van deze
familie niet geanalyseerd konden worden.2 Het fenotype is een progressieve en
symmetrische slechthorendheid van aanvankelijk alleen de hoge tonen. Het
subjectieve gehoorverlies ontstaat tussen de leeftijd van nul tot 40 jaar. Een
statistische analyse van audiometrische gegevens maakt een congenitaal
gehoorverlies in de hoge tonen aannemelijk, van zo’n 30 dB. Op 0.5 kHz en 1 kHz
is het gehoorverlies het meest progressief. Analyse van toon- en spraak-
audiometrische data van de twee DFNA5 families toont een zelfde fenotype wat
betreft de toonaudiometrie, met beter behoud van de spraakdiscriminatie in de
huidige familie.
Genkoppeling-onderzoek van deze tweede DFNA5 familie werd direct opgestart,
omdat de audiometrische data vergelijkbaar waren met de originele DFNA5
familie. Dit bevestigt opnieuw het belang van fenotype-genotype vergelijking.
Een volledige genoomscan was onnodig, waardoor tijd en kosten werden
bespaard. De mutatie bevat een nucleotide verandering in de splice-acceptor site
van intron 7, dat afwezigheid van exon 8 in een deel van de transcripten
veroorzaakt. Aangezien er maar een kleine hoeveelheid van het afwijkend
gentranscript wordt aangetroffen in de huidige familie, lijkt de aanwezigheid van
een dominant negatief effect waarschijnlijk. Dit houdt een type mutatie in waarin
het afwijkende eiwit een complex vormt met het normale eiwit, zodat het niet
meer functioneert. In de originele familie wordt een hoger percentage abnormaal
genprodukt gevonden en ook in de controles is een, zei het zeer kleine,
hoeveelheid aberrant eiwit aanwezig. Het lijkt derhalve alsof er een kritieke
drempel bestaat, waarboven dit afwijkend proteïne schadelijk wordt. De vraag is
nog onbeantwoord of de verschillen in spraakdiscriminatie tussen de twee
DFNA5 families worden veroorzaakt door de verschillende verhoudingen tussen
normaal en afwijkend eiwit.
In Hoofdstuk 3 wordt het cochleovestibulaire en oogheelkundige fenotype van
DFNA9  beschreven.  In Hoofdstuk 3.1 wordt aandacht besteed aan de
cochleovestibulaire disfunctie in een familie met de bekende Nederlands-Vlaamse
founder mutatie in het COCH gen (Pro51Ser). Vervolgens wordt een
gedetailleerde analyse gemaakt van 74 mutatiedragers van de Pro51Ser mutatie,
inclusief de huidige familie. De vestibulo-oculaire reflex, uitgezet tegen de leeftijd,
wordt vergeleken met de gemiddelde toondrempel genomen van 1, 2 en 4 kHz,
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uitgezet tegen dezelfde parameter. Uit deze gegevens kan geconcludeerd worden
dat de vestibulaire disfunctie 100% penetrant is en dat deze ongeveer negen jaar
vooruitloopt op het gehoorverlies. De afname van de evenwichtsfunctie is tevens
progressiever en uiteindelijk vollediger dan de slechthorendheid in patiënten met
de Pro51Ser mutatie. Op 43 jaar is het gehoorverlies net ingetreden terwijl de
vestibulaire disfunctie al bijna compleet is.
Hoofdstuk 3.2 spitst zich toe op de vondst van typische verticale striae in het
anterieure segment van de cornea, in dezelfde familie als wordt beschreven in
hoofdstuk 3.1. Vervolgens zijn nog drie DFNA9 families oogheelkundig
onderzocht om te achterhalen of er een mogelijk oorzakelijk verband bestaat
tussen verticale cornea striae en verschillende mutaties in het COCH gen. Families
1 (Hoofdstuk 3.1) en 2 bezitten de Pro51Ser mutatie, en families 3 en 4
respectievelijk de Gly88Glu en de Gly87Trp mutatie. In totaal zijn 98 familieleden
onderzocht, waarvan 61 mutatiedragers zijn. De verticale cornea striae zijn enkel
zichtbaar na aanbrengen van fluoresceïne. Ze veroorzaken slechts klachten als
droge en branderige ogen en fluctuerende visus, waardoor het aanpassen van een
bril of lenzen zeer moeizaam is. De striae zijn een niet eerder gekend klinisch
verschijnsel in Nederland. De striae zijn aanwezig in 32 familieleden, waarvan 27
mutatiedragers, vanaf een leeftijd van 47 jaar. Statistische analyse vond een
significante associatie tussen verticale cornea striae en de COCH mutaties  in  de
Pro51Ser mutatie in families 1 en 2 en de Gly88Glu mutatie in familie 3. In familie
4 is geen associatie aanwezig. Hoewel vijf personen zonder een mutatie de striae
ook vertonen en er geen associatie wordt gevonden in familie 4, is het naar onze
mening niet waarschijnlijk dat een sequentievariant in een aangrenzend gen de
co-segregatie veroorzaakt. Aangezien de striae aanwezig zijn in drie DFNA9
families met twee verschillende mutaties in het COCH gen en de striae niet
zichtbaar zijn in de oogheelkundige populatie, veronderstellen we dat de verticale
cornea striae en de cochleovestibulaire disfunctie veroorzaakt worden door de
Pro51Ser en de Gly88Glu mutaties in het COCH gen. Dit wordt ondersteund door
de detectie van COCH gen transcripten in de humane cornea en in een cDNA
bibliotheek geproduceerd van RNA van het anterieure oogsegment in
zebravissen.3 Cochline, het genprodukt van COCH, is bovendien gevonden in het
trabekelsysteem in patiënten met primair open hoek glaucoom en in DBA/2J
muizen met glaucoom en progressief gehoorverlies.4,5 Agglomeraten van dit eiwit
met eosinofiele glycosaminoglycanen zijn aangetroffen in de cochlea alsook in het
anterieure gedeelte van het oog.4,6
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In Hoofdstuk 4 wordt tenslotte een DFNA11 familie beschreven. Het genotype
bestaat uit een c.1373A>T nucleotide verandering in exon 13 dat een Asn458Ile
substitutie veroorzaakt in het motor domein van myosine VIIa.7 Het gehoorverlies
start tussen de leeftijd van vier tot 43 jaar en het audiogram heeft een vlakke of
licht afdalende curve. De familie is tevens oogheelkundig onderzocht, aangezien
mutaties in het myosine VIIa gen ook Usher syndroom type 1 veroorzaken, wat
gekenmerkt wordt door vroegkinderlijke doofheid in combinatie met gezichts-
verlies door progressieve retina dystrofie (retinitis pigmentosa). Subklinische
afwijkingen zijn gevonden in deze DFNA11 familie bij gezichtsveldonderzoek,
electroretinografie en electro-oculografie. Dit duidt op delicate afwijkingen ter
hoogte van de fotoreceptor cellen en de pigment epitheel cellen van de retina. De
cochleovestibulaire en oogheelkundige fenotypes zijn vergeleken met de data van
drie andere DFNA11 families. 8-11 Een vijfde DFNA11 familie is pas later
gepubliceerd.12 Het cochleaire fenotype is in alle families praktisch hetzelfde,
hoewel in elke familie een verschillende mutatie werd beschreven in wel drie
verschillende domeinen van het myosine VIIa gen. Bij de andere in de literatuur
gepubliceerde DFNA11 families werden verrassend genoeg geen afwijkingen van
de retina gevonden. 8-12 Mutaties in het myosine VIIa gen kunnen DFNA11, Usher
syndroom type 1 en DFNB2 veroorzaken. In DFNB2 werden ook geen
aanwijzingen gevonden voor retinitis pigmentosa. Het is onduidelijk waarom een
afwijkend myosine VIIa eiwit leidt tot disfunctie in de retina in Usher syndroom
type  1  en  de  beschreven  DFNA11  familie,  terwijl  er  geen  afwijkingen  zijn
gevonden in de andere DFNA11 families of in DFNB2. In het shaker-1 muis
model en het Usher type IB rat model (Myo7atnd-1Hubr)  zijn  ook  geen  ernstige
aberraties in de retina gevonden.13,14 Vervolgonderzoeken zijn nodig om meer
duidelijkheid te verschaffen over het pathofysiologisch mechanisme, zoals
analyse van het oogheelkundig fenotype in de “headbanger” muizen. Deze
knaagdieren bevatten een autosomaal dominante overervende mutatie in het
Myo7a gen en zijn nog niet zorgvuldig oogheelkundig onderzocht.15 Mogelijk dat
hernieuwd oogheelkundig onderzoek bij de eerder gepubliceerde DFNA11
families alsnog de door ons beschreven verfijnde oogheelkundige verschijnselen
kan en zal aantonen.
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Dankwoord
Eindelijk is dit proefschrift klaar. Onderzoek doe je niet alleen en zonder de inzet
van heel veel mensen zou dit proefschrift nooit tot stand zijn gekomen.
Als eerste wil ik professor Cremers bedanken. U bent de drijvende kracht van dit
proefschrift geweest en uw niet te stuiten enthousiasme is aanstekelijk. U gaf mij
de mogelijkheid om een wetenschappelijke stage over erfelijke slechthorendheid
te volbrengen en dankzij u heb ik het onderzoek kunnen voortzetten als promotie
onderzoek. U heeft altijd tijd voor overleg en discussie. De zondag ochtenden op
de koffie zijn memorabel.
Professor Cruysberg wil ik bedanken voor het verrichten van het oogheelkundig
onderzoek, veelal in de weekenden. Ik ben u zeer dankbaar dat u mij wat inzicht
heeft gegeven in de oogheelkunde en voor de tijd die u voor mij hebt vrijgemaakt
voor overleg.
Vervolgens  een  dankwoord  voor  mijn  beide  co-promotoren  Hannie  Kremer  en
Patrick  Huygen.  Beste  Hannie,  jij  bent  een  grote  steun  voor  mij  geweest.  Aan  je
onderbouwende kritieken heb ik zeer veel gehad. Dank voor al je hulp, zeker als
de genetica me boven de pet ging. Beste Patrick, je kennis op het gebied van
wiskunde, fysica en het binnenoor zijn van grote waarde voor mij geweest. Ik
vond het heel bijzonder om met jou te kunnen brainstormen achter de computer.
Vandaag is het precies 35 jaar geleden dat jij promoveerde!
Graag bedank ik ook de staf van de keel-, neus-, en oorheelkunde van het UMC St
Radboud voor de kans die ze me hebben gegeven om te promoveren naast de
opleiding tot keel-, neus-, en oorarts.
Ik ben de families die belangeloos aan dit onderzoek hebben meegewerkt zeer
erkentelijk. Mijn dank gaat ook uit naar de medewerkers van het audiologisch
centrum Nijmegen en Martien Nicolasen, voor de hulp bij het klinisch gedeelte
van het onderzoek. Alle medewerkers van de afdeling Antropogenetica wil ik
bedanken voor alle analyses. Mirjam, dank voor je belangrijke rol in hoofdstuk 2.
Diny Helsper-Peters, super dat je zo snel en zorgvuldig de lay-out hebt verzorgd!
Alle  arts-assistenten KNO: Dirk,  Capi,  Steven,  Bas,  Karien,  Martijn,  Savitri,  Erik,
Niels, Brechtje, Ronald, Myrthe en Liselotte (Charlie’s Angels), Stijn, Rutger, Bart,
Godelieve, Olivier, Sylvia, Robert Jan, Jan-Willem, Ferdinand, Ilse, Anne-Martine
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en Veronique ook heel erg bedankt voor jullie steun en gezelligheid. Menige arts-
assistenten groep is toch wel een tikkeltje jaloers op de manier hoe wij met elkaar
omgaan en de lol die we hebben op en buiten de werkvloer. Ik heb me het laatste
jaar een beetje een afhaker gevoeld bij veel gebeurtenissen, maar dit zal ik dubbel
en dwars goedmaken!
Lieve Liesbeth en Esmeralda, ik ben trots dat jullie mij als paranimfen willen
bijstaan. Jullie hebben mij gesteund als ik me minder “okay” voelde en met jullie
is het altijd lachen. Ik ben blij met jullie.
Al  mijn  vrienden  wil  ik  bedanken  voor  alles  wat  ze  voor  me  zijn.  Ook  al  zie  ik
sommigen tijden niet (Ik kom nu zeker naar Ankara/Istanbul en Londen!), jullie
betekenen zeer veel voor me!
Lieve oma, jij bent mijn “super granny”! Ik weet niet hoeveel kaarsjes je al voor
me op hebt  gestoken.  Ik  vind het  geweldig  dat  ik  je  trouwfoto mocht  gebruiken
voor de voorkant.
Lieve papa en mama, bedankt voor jullie onvoorwaardelijke liefde, steun en
vertrouwen.  Jullie  hebben  Rose  en  mij  altijd  de  ruimte  gegeven  om  ons  te
ontplooien tot de mensen die we nu zijn. Dankjewel voor alles. Lieve Rose, fijn dat
je er altijd voor me bent. Ik ben trots dat jij in maart de eindstreep hebt gehaald en
wens je veel succes in toekomstige carrière. Verlies echter niet uit het oog dat er
nog zoveel meer is dan werk.
Lieve Sander,  C’EST FINI!!!  Dank je  wel  voor  je  geduld en begrip.  Fijn  dat  je  er
altijd voor me bent. Ik houd van je. Nu op naar een volgende fase…………………
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List of abbreviations
ADP adenosine diphosphate
ANCOVA analysis of covariance
ARTA age-related typical audiograms
ATD annual threshold deterioration
ATP adenosine triphosphate
BAEP brainstem auditory evoked potentials
Bp base pairs
dB decibels
cDNA complementary deoxyribonucleic acid
DNA deoxyribonucleic acid
DFN X-linked non-syndromic hearing loss
DFNA autosomal dominant inherited sensorineural hearing loss
DFNB autosomal recessive inherited sensorineural hearing loss
DFNY Y-linked inherited sensorineural hearing loss
DFNM modifier gene locus for hearing impairment
EOG electro-oculography
ERG electroretinography
HL hearing level
Hz hertz
IOP intraocular pressure
IVS intervening sequence
kHz kilo hertz
mRNA messenger ribonucleic acid
MMLV moloney Murine Leukemia Virus
NMD nonsense mediated decay
PTA pure tone average
RNA ribonucleic acid
RT-PCR reverse transcriptase polymerase chain reaction
T time constant
USH Usher syndrome
VOR vestibulo-ocular reflex
Finis coronat opus.
(De voltooiing kroont het werk)
